{"gene":"MMP9","run_date":"2026-04-28T18:30:28","timeline":{"discoveries":[{"year":1989,"finding":"MMP9 (92-kDa type IV collagenase/gelatinase B) was first characterized as a metalloprotease secreted by SV40-transformed human lung fibroblasts, normal human alveolar macrophages, monocytic U937 cells, fibrosarcoma HT1080 cells, and keratinocytes. The preproenzyme (predicted Mr 78,426) contains a 19-amino-acid signal peptide and is secreted as a 92-kDa glycosylated proenzyme. It forms a noncovalent complex with TIMP and can be activated by organomercurials, resulting in removal of 73 amino acids from the NH2-terminus. The active enzyme degrades native types IV and V collagen. Five domains were identified: amino-terminal, zinc-binding, fibronectin-like collagen-binding, carboxyl-terminal hemopexin-like, and a unique proline-rich domain homologous to alpha2(V) collagen.","method":"Protein purification, NH2-terminal sequencing, substrate digestion assays, inhibitor complex analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — original biochemical characterization with purification, sequencing, and functional assays","pmids":["2551898"],"is_preprint":false},{"year":1992,"finding":"MMP-3 (stromelysin) activates proMMP-9 through a stepwise mechanism: MMP-3 first cleaves proMMP-9 at the Glu40-Met41 bond in the propeptide to generate an 86-kDa intermediate, then cleaves Arg87-Phe88 to yield an active 82-kDa form. This was the first demonstration of zymogen activation of one MMP family member by another.","method":"In vitro activation assay, NH2-terminal sequencing, alpha2-macroglobulin binding studies","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with site-specific cleavage site identification","pmids":["1371271"],"is_preprint":false},{"year":1992,"finding":"ProMMP-9 purified from HT1080 fibrosarcoma cells can be activated by 4-aminophenylmercuric acetate (yielding Mr 83,000 intermediate then Mr 67,000 active form), as well as by cathepsin G, trypsin, alpha-chymotrypsin, and MMP-3 (stromelysin 1), but not by plasmin, leukocyte elastase, plasma kallikrein, thrombin, or MMP-1. HOCl partially activates the zymogen. TIMP-1 complexed with proMMP-9 inhibits conversion of the intermediate to the active species. Active MMP-9 degrades type I gelatin rapidly and also cleaves native collagens (alpha2 chain of type I, types III, IV, and V) at non-denaturing temperatures.","method":"Protein purification, activation assays, immunoblot, substrate digestion assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — comprehensive in vitro enzyme characterization with multiple activators and substrates","pmids":["1400481"],"is_preprint":false},{"year":1993,"finding":"The MMP9 gene promoter contains three functionally important motifs — AP-1, NF-κB, and Sp-1 binding sites — that positively contribute to induction by TPA and TNFα. The AP-1 site is indispensable but requires synergistic cooperation with either the NF-κB or Sp-1 site for full induction. TNFα rapidly induces nuclear factors binding to AP-1 and κB elements in OST cells.","method":"Promoter deletion/mutation analysis with luciferase reporter, EMSA/nuclear factor binding assays","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 — deletion and mutation analysis of promoter elements with functional reporter assays","pmids":["8426746"],"is_preprint":false},{"year":1998,"finding":"MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. In MMP-9-null mice, apoptosis, vascularization, and ossification in the growth plate are delayed, causing progressive growth plate lengthening (~8x normal). Bone marrow transplantation with wild-type cells rescues vascularization and ossification, identifying bone-marrow-derived 'chondroclasts' as the relevant MMP-9-expressing cell population. Growth plates from null mice show delayed release of an angiogenic activator in culture, establishing MMP-9 as a controller of angiogenesis.","method":"Gene knockout (null mutation), bone marrow transplantation rescue, histology, in vitro organ culture","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout with rescue experiment, multiple orthogonal readouts","pmids":["9590175"],"is_preprint":false},{"year":1998,"finding":"RECK, a membrane-anchored glycoprotein with EGF-like repeats and serine-protease inhibitor-like domains, suppresses MMP-9 secretion in malignant cells and directly binds to and inhibits MMP-9 proteolytic activity. Restored RECK expression in malignant cells reduces MMP-9 secretion and invasive activity.","method":"cDNA expression screening, invasion assay, purified protein binding and inhibition assays, conditioned medium analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1/2 — purified protein interaction and inhibition assay combined with cellular rescue","pmids":["9789069"],"is_preprint":false},{"year":2000,"finding":"CD44 provides a cell surface docking receptor for proteolytically active MMP-9, and cell surface localization of MMP-9 (via CD44) is required for its ability to promote tumor invasion and angiogenesis. MMP-9 (and MMP-2) proteolytically cleave latent TGF-beta, providing a novel mechanism for TGF-beta activation. MMP-9 localization to normal keratinocyte surfaces is also CD44-dependent and can activate latent TGF-beta.","method":"Co-immunoprecipitation, cell surface localization assays, in vitro TGF-beta cleavage assay, tumor invasion and angiogenesis models","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1/2 — biochemical cleavage assay, receptor-ligand interaction, and functional cellular assays","pmids":["10652271"],"is_preprint":false},{"year":2000,"finding":"MMP-9 is predominantly expressed by inflammatory cells (neutrophils, macrophages, mast cells) rather than by neoplastic keratinocytes in a mouse model of multistage skin carcinogenesis driven by HPV16. MMP-9-null transgenic mice show reduced keratinocyte hyperproliferation at all neoplastic stages and decreased incidence of invasive tumors. Bone marrow chimeras expressing MMP-9 only in hematopoietic cells reconstitute MMP-9-dependent contributions to carcinogenesis, establishing that inflammatory cell-derived MMP-9 promotes tumor progression.","method":"Transgenic knockout mouse, bone marrow transplantation chimeras, histopathology, tumor incidence analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout combined with bone marrow chimera rescue in vivo","pmids":["11081634"],"is_preprint":false},{"year":2000,"finding":"MMP-9 (neutrophil gelatinase B) cleaves IL-8(1-77) at the aminoterminus to generate IL-8(7-77), resulting in a 10- to 27-fold higher potency in neutrophil activation (intracellular Ca2+ increase, gelatinase B secretion, chemotaxis). This enhancement correlates with increased binding to neutrophils and enhanced signaling through CXCR1 but not CXCR2. MMP-9 also degrades CTAP-III, PF-4, and GRO-alpha but leaves RANTES and MCP-2 intact, demonstrating substrate specificity for CXC chemokine processing.","method":"In vitro enzyme cleavage assays, calcium flux assay, chemotaxis assay, receptor binding assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — in vitro cleavage with biochemical characterization and multiple functional readouts","pmids":["11023497"],"is_preprint":false},{"year":2001,"finding":"MMP-9 and NGAL (neutrophil gelatinase-associated lipocalin) form a ~125-kDa complex detectable in urine. NGAL protects MMP-9 from degradation in a dose-dependent manner, thereby preserving MMP-9 enzymatic activity. The complex can be reconstituted in vitro by mixing recombinant MMP-9 and NGAL.","method":"Substrate gel electrophoresis, immunoprecipitation, Western blot, in vitro reconstitution, cell culture overexpression","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1/2 — complex identified by multiple biochemical approaches and reconstituted in vitro","pmids":["11486009"],"is_preprint":false},{"year":2001,"finding":"Thrombospondin-1 (TSP1) suppresses in vivo activation of proMMP-9 and in vitro enzymatic activation of proMMP-9 is suppressed by purified TSP1. Absence of TSP1 in mammary tumor-prone mice results in higher levels of active MMP-9 and increased VEGF/VEGFR2 association, implicating TSP1 as an endogenous regulator of MMP-9 activation.","method":"Transgenic mouse model (TSP1 knockout and overexpression), in vitro proMMP9 activation assay with purified TSP1, VEGFR2 co-precipitation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1/2 — in vitro inhibition assay with purified proteins combined with in vivo genetic model","pmids":["11606713"],"is_preprint":false},{"year":2002,"finding":"MMP-9 induced in bone marrow (BM) cells releases soluble Kit-ligand (sKitL) from the bone marrow niche, enabling transfer of hematopoietic and endothelial stem cells from quiescent to proliferative niches. BM ablation induces SDF-1, which upregulates MMP-9 expression, causing shedding of sKitL and recruitment of c-Kit+ stem/progenitors. In MMP-9-/- mice, sKitL release and HSC motility are impaired; exogenous sKitL restores hematopoiesis and survival.","method":"MMP-9 knockout mice, BM ablation, SDF-1 stimulation, exogenous sKitL rescue, stem cell mobilization assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout with molecular rescue, identifies specific substrate (sKitL) shedding mechanism","pmids":["12062105"],"is_preprint":false},{"year":2002,"finding":"MMP-9 and MMP-2 work in concert to produce aortic aneurysms in a mouse model; neither MMP-9KO nor MMP-2KO mice develop aneurysms following CaCl2 application. Reinfusion of wild-type macrophages into MMP-9KO mice reconstitutes AAA formation, but not in MMP-2KO mice, indicating macrophage-derived MMP-9 and mesenchymal cell MMP-2 play distinct and cooperative roles.","method":"Genetic knockout mice, experimental AAA induction, macrophage reinfusion rescue experiment","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — double knockout and cell-specific rescue experiment","pmids":["12208863"],"is_preprint":false},{"year":2002,"finding":"MMP-9 and MMP-2 are shed by endothelial cells as components of membrane vesicles (300–600 nm) in both pro- and active forms. Shedding is stimulated by serum and angiogenic factors FGF-2 and VEGF. Shed vesicles stimulate autocrine endothelial cell invasion through Matrigel and cord formation, establishing vesicle-based MMP secretion as a mechanism for focalized proteolytic activity during angiogenesis.","method":"Ultrastructural analysis, zymography, Western blot, immunogold labeling, invasion and morphogenesis assays","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods identifying vesicle-associated MMP-9 with functional consequence","pmids":["11839588"],"is_preprint":false},{"year":2002,"finding":"MMP9 is specifically induced in premetastatic lung endothelial cells and macrophages by distant primary tumors via VEGFR-1/Flt-1 tyrosine kinase signaling, and this induction significantly promotes lung-specific metastasis. Deletion of VEGFR-1 TK or MMP9 markedly reduces lung metastasis in mice.","method":"Genetic deletion of VEGFR-1 TK and MMP9 in mice, experimental metastasis assays, immunohistochemistry in human samples","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — double genetic approach with in vivo metastasis readout","pmids":["12398893"],"is_preprint":false},{"year":2003,"finding":"tPA upregulates MMP-9 via LRP (low-density lipoprotein receptor-related protein) signaling in brain endothelial cells. RNAi knockdown of LRP abolished tPA-induced MMP-9 upregulation. MMP-9 levels were lower in tPA-knockout mice after focal ischemia, demonstrating that tPA-LRP signaling drives MMP-9-mediated neurovascular matrix degradation in stroke.","method":"RNAi knockdown, tPA knockout mice, focal ischemia model, cell culture MMP-9 measurement","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — RNAi epistasis and genetic knockout in vivo","pmids":["12960961"],"is_preprint":false},{"year":2003,"finding":"Hepatic injury induces MMP-9 activity in the liver, which together with SDF-1 and HGF promotes recruitment of human CD34+ hematopoietic progenitors to the liver. MMP-9 activity is induced by irradiation or inflammation and contributes to CXCR4 upregulation and SDF-1-mediated progenitor homing.","method":"In vivo mouse liver injury model, MMP-9 activity measurement, CXCR4 neutralization, NOD/SCID engraftment assay","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo model with functional readout but MMP-9's direct substrate in this context not fully defined","pmids":["12865405"],"is_preprint":false},{"year":2006,"finding":"Cited2, a CBP/p300-binding transcriptional co-activator, physically associates with Smad2 and Smad3 (confirmed by co-IP, mammalian two-hybrid, and GST pull-down) and enhances TGF-β-mediated upregulation of MMP9. p300 further enhances the Cited2-Smad3 interaction. Chromatin immunoprecipitation showed Cited2 and Smad3 are recruited to the MMP9 promoter upon TGF-β stimulation. Knockdown of Cited2 in MDA-MB-231 cells attenuates TGF-β-mediated MMP9 upregulation and cell invasion.","method":"Co-IP, mammalian two-hybrid, GST pull-down, ChIP, luciferase reporter, siRNA knockdown, invasion assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal protein interaction methods combined with ChIP and functional invasion assay","pmids":["16619037"],"is_preprint":false},{"year":2007,"finding":"Human neutrophils uniquely release TIMP-free proMMP-9 from their granules, which upon activation is a potent proangiogenic stimulus at subnanogram levels on the chick chorioallantoic membrane. TIMP-1 complexation abolishes the proangiogenic activity of neutrophil proMMP-9, demonstrating that the TIMP-free status and catalytic activity of the activated enzyme are both required for the angiogenic response.","method":"Granule purification, in vivo chick CAM angiogenesis assay, stoichiometric TIMP-1 complexation, MMP activity assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1/2 — purified protein functional assay in vivo with biochemical characterization of TIMP-free status","pmids":["18077379"],"is_preprint":false},{"year":2008,"finding":"MMP-9-positive neutrophil infiltration is associated with blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. The cleaved 85-kDa active form of MMP-9 is elevated in hemorrhagic areas, and laser capture microdissection confirmed high MMP-9 in microvessel endothelium and surrounding neutrophils at hemorrhagic sites.","method":"Gelatin zymography, immunohistochemistry, laser capture microdissection, human stroke tissue analysis","journal":"Stroke","confidence":"Medium","confidence_rationale":"Tier 2 — direct tissue analysis with multiple methods but observational in human samples","pmids":["18323498"],"is_preprint":false},{"year":2011,"finding":"Concomitant deficiency of MMP9 and uPA (but not tPA alone or uPAR alone) impairs normal gestation in mice. Combined lack of MMP9 and uPA exacerbates effects on bone growth and shows additive effects on cutaneous wound healing. MMP9 deficiency in wounds leads to compensatory upregulation of uPA activity, revealing a functional dependency between MMP9 and uPA in tissue repair.","method":"Double-gene knockout mice (MMP9/uPA, MMP9/tPA, MMP9/uPAR), gestation analysis, bone measurement, wound healing assay, uPA activity measurement","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis via multiple double-knockout combinations with defined phenotypes","pmids":["21802414"],"is_preprint":false},{"year":2013,"finding":"MMP-9 is a multidomain enzyme with hemopexin (PEX), O-glycosylated, and catalytic domains supporting attachment, articulation, and catalysis, respectively. ProMMP-9 activation involves MMP-3 priming; meprins may destabilize the aminoterminus–fibronectin repeat interaction, and autocatalytic activation can occur when molecules bind the catalytic site displacing the cysteine from the zinc ion. The substrate repertoire extends from ECM to membrane-bound and intracellular proteins including crystallins, tubulins, and actins. The PEX domain exerts non-catalytic anti-apoptotic signaling. MMP-9 oligomers and heteromers (e.g., with NGAL) have distinct biological properties.","method":"Review synthesizing structural biology, degradomics, knockout mouse phenotype analysis, biochemical activation studies","journal":"Critical reviews in biochemistry and molecular biology","confidence":"High","confidence_rationale":"Tier 1/2 — comprehensive synthesis with direct experimental evidence across multiple labs; foundational mechanistic review","pmids":["23547785"],"is_preprint":false},{"year":2013,"finding":"ADAM17 mediates LPS-induced MMP9 expression in lung epithelial cells (A549) via TNF-α/NF-κB signaling. Lentiviral RNAi knockdown of ADAM17 inhibits TNF-α shedding into supernatants, reduces IκBα phosphorylation and p65 phosphorylation, and decreases MMP9 expression in response to LPS, placing ADAM17 upstream of MMP9 in this pathway.","method":"Lentiviral RNAi, pharmacological NF-κB inhibitor (PDTC), TNFR1 blocking peptide, Western blot, ELISA","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — RNAi epistasis with pharmacological confirmation in cell culture","pmids":["23341882"],"is_preprint":false},{"year":2014,"finding":"TRPV4 activation provides a Ca2+ source necessary for rapid release and activation of MMP2 and MMP9 in intact mouse lung, contributing to septal barrier disruption and lung injury. TRPV4-/- lungs do not show MMP activation upon agonist treatment, and pharmacological MMP2/9 blockade (SB-3CT) protects against TRPV4-induced injury. TIMP-2 levels are decreased in TRPV4-injured lungs, increasing availability of active MMPs.","method":"TRPV4 knockout mice, TRPV4 agonist perfusion, Western blot for active MMP isoforms, pharmacological MMP inhibition, lung injury assessment","journal":"American journal of physiology. Lung cellular and molecular physiology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic and pharmacological approaches in intact organ model","pmids":["25150065"],"is_preprint":false},{"year":2014,"finding":"Glioma cells induce MMP9 expression in microglia/macrophages via Toll-like receptor 2/6 (TLR2/6) signaling and p38 MAPK. TLR2-deficient mice show attenuated microglial MMP9 upregulation in experimental gliomas. Minocycline and p38 MAPK antagonists attenuate MMP9 and TLR2 upregulation in vitro. Glioma supernatant also upregulates TLR2 expression in microglia.","method":"TLR2-knockout mice, experimental glioma model, in vitro macrophage stimulation, minocycline and p38 inhibitor treatment","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — genetic knockout in vivo with pharmacological confirmation in vitro","pmids":["24752463"],"is_preprint":false},{"year":2014,"finding":"ADAM15 upregulates MMP9 expression in lung cancer cells via MEK-ERK pathway activation and also proteolytically cleaves and activates pro-MMP9 directly in vitro, while interacting with MMP9 in vivo. Knockdown of MMP9 attenuates the invasive promotion by ADAM15 overexpression, placing ADAM15 as both an upstream regulator and direct activator of MMP9.","method":"shRNA knockdown, co-immunoprecipitation, in vitro pro-MMP9 cleavage assay, MEK-ERK inhibitor treatment, invasion assays","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro cleavage assay and co-IP with functional epistasis by knockdown","pmids":["26323669"],"is_preprint":false},{"year":2015,"finding":"Endothelin-1 controls ventricular superoxide levels, which regulate MMP9 expression. In endothelin-1 hypomorphic mice, increased ventricular superoxide drives MMP9 overexpression, leading to reduced ventricular stiffness and dilated cardiomyopathy. A superoxide dismutase mimetic normalizes superoxide levels and reduces MMP9 overexpression, substantially improving cardiac function. Genetic ablation of MMP9 also improves cardiac function (without reducing superoxide), placing MMP9 downstream of superoxide in cardiac remodeling.","method":"Hypomorphic/hypermorphic allele mouse model, Cre-loxP switching, SOD mimetic treatment, MMP9 knockout, cardiac functional measurements","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — genetic and pharmacological epistasis with multiple alleles and rescue experiments","pmids":["25848038"],"is_preprint":false},{"year":2015,"finding":"ATP6V1H deficiency in zebrafish dramatically increases mmp9 (and mmp13) expression, leading to reduced calcified bone cells and bone defects. Treatment of mutant embryos with MMP9/MMP13 small molecule inhibitors significantly restores bone mass, placing MMP9 downstream of V-ATPase activity in a pathway controlling bone formation.","method":"CRISPR/Cas9 knockout in zebrafish, pharmacological MMP inhibition rescue, skeletal staining, gene expression analysis","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 — genetic knockout with pharmacological rescue in vertebrate model","pmids":["28158191"],"is_preprint":false},{"year":2020,"finding":"MMP9 promotes mesenchymal transition of pancreatic ductal adenocarcinoma cells via cleavage and activation of PAR1 (protease-activated receptor 1). Macrophage-secreted MMP9 was identified as the relevant PAR1 agonist by protease profiling and PAR1 cleavage assays. Inhibition of MMP9 and/or PAR1 limits macrophage-driven mesenchymal transition and reduces tumor cell survival against macrophage anti-tumor activity.","method":"PAR1 cleavage assays, MMP9/PAR1 inhibitors, medium transfer experiments, siRNA knockdown of ZEB1, tissue microarray correlation","journal":"Cellular oncology (Dordrecht, Netherlands)","confidence":"Medium","confidence_rationale":"Tier 2 — protease cleavage assay identifying specific substrate combined with inhibitor and knockdown experiments","pmids":["32809114"],"is_preprint":false},{"year":2020,"finding":"Constitutive expression of MMP9 in the colonic epithelium (TgM9 mice) reduces reactive oxygen species, decreases DNA damage, and increases mismatch repair gene expression during colitis-associated cancer, suppressing tumor development via an 'MMP9-Notch1-ARF-p53 axis'. MMP9 siRNA-loaded nanoparticles that silence MMP9 in the colon increase ROS and DNA damage, confirming MMP9's tumor suppressor role in this context.","method":"Transgenic mouse model, siRNA nanoparticle knockdown, ROS measurement, DNA damage assays, mismatch repair gene expression","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — transgenic gain-of-function and siRNA loss-of-function with defined molecular readouts","pmids":["32943603"],"is_preprint":false},{"year":2021,"finding":"Glucocorticoid-mediated stress enhances secretory autophagy via the stress-responsive co-chaperone FKBP51 (FK506-binding protein 51), leading to MMP9 secretion. Stress-enhanced MMP9 secretion increases cleavage of proBDNF to its mature form (mBDNF), as demonstrated by cellular assays and in vivo microdialysis, linking the stress response to synaptic plasticity via MMP9-mediated proBDNF processing.","method":"Cellular secretory autophagy assays, in vivo microdialysis, FKBP51 manipulation, proBDNF/mBDNF cleavage assays","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo and in vitro evidence linking stress-induced MMP9 secretion to specific substrate cleavage","pmids":["34330919"],"is_preprint":false},{"year":2021,"finding":"PPARγ downregulates MMP9 expression after intracerebral hemorrhage by inhibiting NF-κB. Activation of PPARγ with rosiglitazone decreases NF-κB and MMP9; NF-κB inhibition (JSH-23) also suppresses MMP9 with limited effect on PPARγ. Protein co-IP confirmed direct interactions of NF-κB with PPARγ and MMP9 gene, and ChIP confirmed NF-κB binding to MMP9 promoter.","method":"In vivo and in vitro PPARγ agonist/antagonist treatment, NF-κB inhibitor, co-IP, ChIP, Western blot","journal":"Neuroscience letters","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and co-IP combined with pharmacological epistasis in vivo and in vitro","pmids":["33636289"],"is_preprint":false},{"year":2021,"finding":"Macrophage migration through ECM requires both MMP9-mediated degradation (mesenchymal migration mode) and Rac GTPase signaling. Inhibition of MMPs or Rac abolishes ECM degradation by macrophages and suppresses their ability to mobilize hematopoietic stem/progenitor cells in zebrafish embryos, demonstrating that MMP9-dependent mesenchymal migration is functionally linked to HSPC mobilization.","method":"Live imaging in zebrafish embryos, MMP inhibitors, Rac inhibitors, morphometric analysis, HSPC mobilization assay","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — real-time imaging with pharmacological inhibition and functional readout in vivo","pmids":["33980872"],"is_preprint":false},{"year":2022,"finding":"HOCl (generated by an enzymatic MPO/H2O2/Cl- system) activates proMMP9 via oxidation of the cysteine switch mechanism, as demonstrated by fluorescence activity assays and gel zymography. Low nanomolar-to-low micromolar concentrations of chloramines formed from amino acids, serum albumin, and ECM proteins (laminin, fibronectin) also activate proMMP9, and this activation is diminished by the competitive HOCl-reactive species methionine. High HOCl concentrations inactivate active MMP9, establishing a concentration-dependent bidirectional redox regulation.","method":"Fluorescence activity assays, gel zymography, MPO enzymatic system, chloramine preparation, competitive inhibition with methionine","journal":"Antioxidants (Basel, Switzerland)","confidence":"High","confidence_rationale":"Tier 1 — in vitro biochemical reconstitution with multiple oxidant species and competitive inhibition controls","pmids":["36009335"],"is_preprint":false},{"year":2023,"finding":"LCN2, LOXL2, and MMP9 form a ternary protein complex: LCN2-LOXL2 and LCN2-MMP9 interactions occur both intracellularly and extracellularly, while LOXL2-MMP9 interactions only occur intracellularly. The LCN2/LOXL2/MMP9 complex enhances ECM proteolytic activity (fibronectin and Matrigel degradation), filopodia formation, microfilament rearrangement via profilin-1 upregulation, SPOCK1 expression, and FAK/AKT/GSK3β pathway activation.","method":"Protein-protein interaction assays (co-IP, PLA), co-overexpression functional studies, matrix degradation assays, in vivo tumor models, pathway analysis","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 — protein interaction assays with functional downstream pathway characterization","pmids":["37753805"],"is_preprint":false},{"year":2024,"finding":"Active MMP9 drives ferroptosis by directly interacting with GPX4 (glutathione peroxidase 4) and glutathione reductase, reducing GPX4 expression and activity. MMP9 suppresses key transcription factors (SP1, CREB1, NRF2, FOXO3, ATF4) and GPX1 and FSP1, disrupting cellular redox balance. MMP9 also regulates iron metabolism by modulating iron import, storage, and export through a network of protein interactions. LC-MS/MS identified 83 proteins interacting with MMP9 at subcellular levels implicated in ferroptosis regulation.","method":"Engineered MMP9 construct without collagenase activity, LC-MS/MS protein interaction mapping, GPX4 activity assays, transcription factor expression analysis, integrated pathway analysis","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 — novel MMP9 construct combined with MS-based interactome and functional enzyme assays; single lab","pmids":["39252956"],"is_preprint":false},{"year":2024,"finding":"Dysadherin directly targets MMP9, and the dysadherin/MMP9 axis enhances ECM proteolytic activity, promotes CRC cell invasiveness, activates cancer-associated fibroblasts, and orchestrates ECM remodeling. In a humanized mouse model, dysadherin knockout reduces immunosuppressive and proangiogenic microenvironment, and these effects are reversed by MMP9 overexpression.","method":"Co-IP/direct targeting assays, MMP9 overexpression rescue, dysadherin knockout mouse model, ECM proteolytic activity assays, humanized mouse model","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding assay with genetic rescue in mouse model","pmids":["39613801"],"is_preprint":false},{"year":1996,"finding":"The 92-kDa type IV collagenase gene (CLG4B/MMP9) was remapped from human chromosome 16 to chromosome 20 using somatic cell hybrid panel screening, FISH, and linkage analysis with a newly identified polymorphism.","method":"Somatic cell hybrid panel, FISH, linkage analysis","journal":"Cytogenetics and cell genetics","confidence":"High","confidence_rationale":"Tier 1 — three independent mapping methods converge on chromosomal localization","pmids":["8978762"],"is_preprint":false},{"year":2020,"finding":"MMP-9 mediates Syndecan-4 (Sdc4) shedding under osteoarthritis conditions. MMP-9 (but not MMP-2) is elevated in cartilage, synovial membrane, and synovial fluid of OA patients and correlates with shed Sdc4 levels. siRNA knockdown and pharmacological inhibition of MMP-9 decrease shed Sdc4 in vitro. Increased Sdc4 shedding results in reduced ERK phosphorylation upon IL-1β stimulation, desensitizing chondrocytes to IL-1 signaling.","method":"siRNA knockdown, MMP inhibitors, ELISA, IHC, RT-qPCR, Western blot (pERK/ERK)","journal":"Osteoarthritis and cartilage","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA and inhibitor evidence for MMP-9 as sheddase with defined downstream signaling consequence","pmids":["33246160"],"is_preprint":false},{"year":2021,"finding":"MMP-9 interacts with CD44 via its hemopexin (PEX) domain on the cell surface, while the catalytic domain cleaves CD44. A bispecific inhibitor (C9-PEX) simultaneously targeting both MMP9 catalytic and PEX domains and CD44 reduces MMP9 cellular levels, interferes with MMP9 homodimerization, and inhibits activation of the downstream MAPK/ERK pathway, demonstrating functional roles of both MMP9 domains in cancer cell invasiveness.","method":"Yeast surface display engineering, bispecific inhibitor design, cell-based functional assays for invasion, MMP9 dimerization assays, MAPK/ERK pathway analysis","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 — domain-specific engineered inhibitors with multiple functional readouts","pmids":["33600567"],"is_preprint":false}],"current_model":"MMP9 (gelatinase B) is a multidomain zinc-dependent endopeptidase secreted as a proenzyme that is activated extracellularly by MMP-3 (stromelysin) cleavage, by oxidants including HOCl/myeloperoxidase, and by ADAM15; its activity is regulated by TIMP-1/NGAL complex formation, RECK, thrombospondin-1, and cell-surface docking via CD44 or membrane vesicle shedding; it degrades ECM components (types I, III, IV, V collagen, gelatin, fibronectin, laminin) and non-ECM substrates including pro-TGF-β, IL-8 (potentiating chemotaxis), proBDNF, and Syndecan-4, and it controls critical biological processes including growth plate vascularization, hematopoietic stem cell mobilization (via Kit-ligand shedding), tumor angiogenesis (particularly as TIMP-free enzyme from neutrophils), bone marrow niche regulation, blood-brain barrier integrity, ferroptosis (via GPX4 and iron metabolism modulation), and synaptic plasticity; its transcription is driven by AP-1/NF-κB/Sp-1 promoter elements in response to TNFα, TPA, and tPA-LRP signaling, and is regulated epigenetically by DNA methylation and by upstream pathways including PPARγ-NF-κB, EGFR-PI3K-Akt, ERK/MAPK, and TLR2/p38 signaling."},"narrative":{"teleology":[{"year":1989,"claim":"Identification of MMP9 as a distinct 92-kDa secreted metalloproteinase with a five-domain architecture and type IV/V collagenase activity established it as a new MMP family member with unique structural features including a collagen V-homologous proline-rich domain.","evidence":"Protein purification, NH2-terminal sequencing, substrate digestion assays from SV40-transformed fibroblasts, macrophages, and fibrosarcoma cells","pmids":["2551898"],"confidence":"High","gaps":["Crystal structure of full-length proMMP-9 not yet resolved","Physiological activators in vivo unknown"]},{"year":1992,"claim":"Demonstration that MMP-3 activates proMMP-9 through sequential propeptide cleavage at specific bonds (Glu40-Met41, Arg87-Phe88) established the paradigm of inter-MMP zymogen activation cascades, while TIMP-1 was shown to block intermediate-to-active conversion.","evidence":"In vitro reconstitution with purified enzymes, NH2-terminal sequencing of cleavage products, substrate digestion with multiple protease panels","pmids":["1371271","1400481"],"confidence":"High","gaps":["Relative contributions of different activators in specific tissue contexts unknown","Structural basis of TIMP-1 inhibition of the intermediate not resolved"]},{"year":1993,"claim":"Mapping the transcriptional control of MMP9 to synergistic AP-1, NF-κB, and Sp-1 promoter elements explained how inflammatory cytokines (TNF-α) and phorbol esters (TPA) drive MMP9 induction, establishing the transcriptional framework for MMP9 regulation.","evidence":"Promoter deletion/mutation luciferase reporters, EMSA nuclear factor binding assays in osteosarcoma cells","pmids":["8426746"],"confidence":"High","gaps":["Chromatin-level regulation (histone modifications, DNA methylation) not yet examined","Cell-type-specific enhancer usage not defined"]},{"year":1998,"claim":"MMP9-null mice revealed that MMP9 is required for growth plate vascularization, hypertrophic chondrocyte apoptosis, and ossification, and bone marrow transplantation rescue proved that bone-marrow-derived cells are the critical MMP9 source, establishing MMP9 as an angiogenic switch in skeletal development.","evidence":"Gene knockout mice, bone marrow transplantation rescue, organ culture angiogenesis assays","pmids":["9590175"],"confidence":"High","gaps":["Direct angiogenic substrate released by MMP9 in growth plate not molecularly identified","Redundancy with other MMPs in ossification not fully tested"]},{"year":2000,"claim":"Three discoveries converged to define MMP9's non-ECM substrate repertoire and cell-surface regulation: CD44 was identified as a docking receptor localizing active MMP9 to the cell surface for TGF-β activation; inflammatory cell-derived MMP9 was shown to drive multistage skin carcinogenesis; and MMP9 was found to process IL-8 into a 10–27-fold more potent neutrophil chemotactic form.","evidence":"Co-immunoprecipitation and TGF-β cleavage assays; bone marrow chimera experiments in HPV16 transgenic mice; in vitro IL-8 cleavage with Ca²⁺ flux and chemotaxis readouts","pmids":["10652271","11081634","11023497"],"confidence":"High","gaps":["Full repertoire of non-ECM substrates not systematically catalogued","Structural basis of CD44–MMP9 PEX domain interaction not resolved at atomic level"]},{"year":2001,"claim":"Discovery that NGAL stabilizes MMP9 against degradation (preserving enzymatic activity) and that thrombospondin-1 suppresses proMMP-9 activation in vivo revealed two opposing extracellular regulators that tune MMP9 bioavailability beyond TIMP-based inhibition.","evidence":"In vitro reconstitution of NGAL–MMP9 complex; TSP1-knockout/overexpression mice with in vitro activation suppression assays","pmids":["11486009","11606713"],"confidence":"High","gaps":["Stoichiometry and structural basis of NGAL–MMP9 complex not fully defined","Whether TSP1 directly binds proMMP9 or acts indirectly not conclusively resolved"]},{"year":2002,"claim":"MMP9 was placed at the center of hematopoietic stem cell mobilization: SDF-1-induced MMP9 releases soluble Kit-ligand from the bone marrow niche, enabling c-Kit+ stem cell transfer to proliferative niches, as demonstrated by impaired sKitL release and HSC motility in MMP9−/− mice rescued by exogenous sKitL.","evidence":"MMP9 knockout mice, BM ablation, exogenous sKitL rescue, stem cell mobilization assays","pmids":["12062105"],"confidence":"High","gaps":["Whether MMP9 cleaves Kit-ligand directly or via intermediate protease not fully resolved","Contribution of other MMPs to sKitL shedding not excluded"]},{"year":2002,"claim":"Parallel discoveries showed MMP9 contributes to aortic aneurysm formation (cooperatively with MMP-2 from distinct cell sources) and is released on membrane vesicles by endothelial cells during angiogenesis, while MMP9 induction in premetastatic lungs via VEGFR-1 signaling promotes metastatic colonization.","evidence":"Double-KO mice with macrophage reinfusion for AAA; vesicle ultrastructure/zymography/invasion assays; VEGFR-1 TK and MMP9 deletion metastasis models","pmids":["12208863","11839588","12398893"],"confidence":"High","gaps":["Specific ECM substrates degraded by vesicle-associated MMP9 not identified","Whether vesicle-mediated MMP9 delivery is regulated independently of soluble secretion unknown"]},{"year":2003,"claim":"tPA was shown to upregulate MMP9 expression in brain endothelium via LRP signaling, linking the fibrinolytic system to MMP9-mediated blood-brain barrier degradation during stroke.","evidence":"RNAi knockdown of LRP, tPA-knockout mice, focal cerebral ischemia model","pmids":["12960961"],"confidence":"High","gaps":["Downstream signaling cascade from LRP to MMP9 transcription not fully delineated","Whether LRP-MMP9 axis is relevant in non-stroke neurological injury unknown"]},{"year":2007,"claim":"The discovery that neutrophils uniquely release TIMP-free proMMP-9—which upon activation is an exceptionally potent proangiogenic stimulus at subnanomolar concentrations—explained why neutrophil-derived MMP9 has disproportionate biological impact compared to MMP9 from other sources.","evidence":"Granule purification, stoichiometric TIMP-1 complexation, in vivo chick CAM angiogenesis assay","pmids":["18077379"],"confidence":"High","gaps":["Mechanism by which neutrophils package MMP9 without TIMP not determined","Whether TIMP-free status is regulated under different inflammatory conditions unclear"]},{"year":2015,"claim":"Endothelin-1/superoxide/MMP9 epistasis experiments established MMP9 as an effector of oxidative-stress-driven cardiac remodeling: superoxide upregulates MMP9, and genetic ablation of MMP9 rescues dilated cardiomyopathy independently of superoxide levels.","evidence":"Endothelin-1 hypomorphic mice, SOD mimetic rescue, MMP9 knockout, cardiac functional measurements","pmids":["25848038"],"confidence":"High","gaps":["Specific cardiac ECM substrates degraded by MMP9 in this context not identified","Whether MMP9 catalytic activity or non-catalytic PEX signaling mediates the phenotype unclear"]},{"year":2020,"claim":"MMP9's substrate repertoire was extended to include PAR1 on pancreatic cancer cells (promoting mesenchymal transition) and Syndecan-4 in osteoarthritic cartilage (desensitizing chondrocytes to IL-1β signaling), demonstrating context-specific signaling consequences of MMP9-mediated ectodomain shedding.","evidence":"PAR1 cleavage assays with MMP9/PAR1 inhibitors; Sdc4 siRNA/inhibitor knockdown with pERK readout in chondrocytes","pmids":["32809114","33246160"],"confidence":"Medium","gaps":["Structural determinants of MMP9 selectivity for PAR1 vs other PARs not defined","In vivo validation of Sdc4 shedding by MMP9 in animal OA models lacking"]},{"year":2021,"claim":"MMP9 was linked to stress-induced synaptic plasticity: glucocorticoid-driven secretory autophagy via FKBP51 releases MMP9, which cleaves proBDNF to mature BDNF in vivo, connecting neuroendocrine stress signaling to MMP9-dependent neurotrophin processing.","evidence":"Cellular secretory autophagy assays, in vivo brain microdialysis, FKBP51 manipulation, proBDNF/mBDNF cleavage measurement","pmids":["34330919"],"confidence":"Medium","gaps":["Whether MMP9 cleaves proBDNF directly or via plasmin cascade not fully distinguished","Relevance to chronic stress and psychiatric phenotypes not established in knockout models"]},{"year":2022,"claim":"Biochemical reconstitution of the HOCl/myeloperoxidase-mediated cysteine switch oxidation mechanism showed concentration-dependent bidirectional regulation: low-concentration oxidants activate proMMP9, while high concentrations inactivate the enzyme, providing a rheostat for inflammatory MMP9 control.","evidence":"Fluorescence activity assays, gel zymography, MPO enzymatic system, competitive methionine inhibition","pmids":["36009335"],"confidence":"High","gaps":["In vivo concentrations of HOCl at inflammatory sites relative to activation/inactivation thresholds not measured","Whether other MMPs share the same bidirectional redox sensitivity unknown"]},{"year":2024,"claim":"Two studies expanded MMP9 biology into ferroptosis and tumor microenvironment remodeling: MMP9 was found to interact with GPX4 and modulate iron metabolism to drive ferroptosis, and the dysadherin–MMP9 axis was shown to activate cancer-associated fibroblasts and remodel the immunosuppressive microenvironment.","evidence":"LC-MS/MS interactome mapping with engineered MMP9 construct and GPX4 activity assays; co-IP/knockout rescue in humanized mouse model for dysadherin–MMP9","pmids":["39252956","39613801"],"confidence":"Medium","gaps":["MMP9–GPX4 interaction mechanism (catalytic cleavage vs binding-mediated inhibition) not distinguished","Ferroptosis findings from single lab with engineered construct require independent replication","Dysadherin–MMP9 binding interface not structurally characterized"]},{"year":null,"claim":"Key unresolved questions include the structural basis of full-length MMP9 activation and substrate selection, the relative in vivo contributions of catalytic versus non-catalytic (PEX domain) functions, and whether MMP9-driven ferroptosis and intracellular roles represent physiologically relevant activities or artifacts of overexpression systems.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution structure of full-length proMMP9 in complex with activators or substrates","Catalytic vs PEX-mediated non-catalytic signaling contributions not genetically separated in vivo","Intracellular MMP9 substrates (tubulins, crystallins) lack in vivo validation"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,2,8,28,38]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,2,6,33]}],"localization":[{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[0,4,6,34,36]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,9,13,18]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[6,39]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[13]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[0,2,4,12,34,36]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,8,14,18,24]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,6,15,22,31]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[4,27]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[11,32]}],"complexes":["proMMP-9/TIMP-1 complex","MMP-9/NGAL (LCN2) complex","LCN2/LOXL2/MMP9 ternary complex"],"partners":["TIMP1","LCN2","CD44","MMP3","RECK","THBS1","ADAM15","LOXL2"],"other_free_text":[]},"mechanistic_narrative":"MMP9 (gelatinase B) is a secreted zinc-dependent endopeptidase that functions as a central regulator of extracellular matrix remodeling, angiogenesis, and immune cell mobilization. Secreted as a 92-kDa glycosylated proenzyme, it is activated by MMP-3-mediated stepwise propeptide cleavage, by HOCl/myeloperoxidase-generated oxidants acting on the cysteine switch, and by ADAM15, while its activity is constrained by TIMP-1 complexation, RECK, and thrombospondin-1 [PMID:1371271, PMID:36009335, PMID:9789069, PMID:11606713]. MMP9 degrades collagens (types I, III, IV, V), gelatin, and non-ECM substrates including latent TGF-β (via CD44-mediated cell-surface docking), IL-8 (potentiating neutrophil chemotaxis ~10-fold), Kit-ligand (enabling hematopoietic stem cell mobilization from bone marrow niches), Syndecan-4, PAR1, and proBDNF, thereby linking proteolysis to angiogenesis, stem cell trafficking, inflammation, and synaptic plasticity [PMID:10652271, PMID:11023497, PMID:12062105, PMID:33246160, PMID:34330919]. Transcription is driven by cooperative AP-1, NF-κB, and Sp-1 promoter elements in response to TNF-α, TPA, tPA-LRP signaling, and TLR2/p38 signaling, with PPARγ serving as a negative regulator through NF-κB inhibition [PMID:8426746, PMID:12960961, PMID:33636289]."},"prefetch_data":{"uniprot":{"accession":"P14780","full_name":"Matrix metalloproteinase-9","aliases":["92 kDa gelatinase","92 kDa type IV collagenase","Gelatinase B","GELB"],"length_aa":707,"mass_kda":78.5,"function":"Matrix metalloproteinase that plays an essential role in local proteolysis of the extracellular matrix and in leukocyte migration (PubMed:12879005, PubMed:1480034, PubMed:2551898). Could play a role in bone osteoclastic resorption (By similarity). Cleaves KiSS1 at a Gly-|-Leu bond (PubMed:12879005). Cleaves NINJ1 to generate the Secreted ninjurin-1 form (PubMed:32883094). Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments (PubMed:1480034). Degrades fibronectin but not laminin or Pz-peptide","subcellular_location":"Secreted, extracellular space, extracellular matrix","url":"https://www.uniprot.org/uniprotkb/P14780/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MMP9","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MMP9","total_profiled":1310},"omim":[{"mim_id":"619550","title":"RAB40B, MEMBER RAS ONCOGENE FAMILY; RAB40B","url":"https://www.omim.org/entry/619550"},{"mim_id":"619105","title":"MICRO RNA 30E; MIR30E","url":"https://www.omim.org/entry/619105"},{"mim_id":"618335","title":"LONG INTERGENIC NONCODING RNA 958; LINC00958","url":"https://www.omim.org/entry/618335"},{"mim_id":"617801","title":"CYCLASE-ASSOCIATED ACTIN CYTOSKELETON REGULATORY PROTEIN 1; CAP1","url":"https://www.omim.org/entry/617801"},{"mim_id":"616177","title":"DDRGK DOMAIN-CONTAINING PROTEIN 1; DDRGK1","url":"https://www.omim.org/entry/616177"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":355.6},{"tissue":"lymphoid tissue","ntpm":102.5}],"url":"https://www.proteinatlas.org/search/MMP9"},"hgnc":{"alias_symbol":[],"prev_symbol":["CLG4B"]},"alphafold":{"accession":"P14780","domains":[{"cath_id":"-","chopping":"42-96","consensus_level":"high","plddt":83.8131,"start":42,"end":96},{"cath_id":"3.40.390.10","chopping":"121-214_393-444","consensus_level":"medium","plddt":90.4663,"start":121,"end":444},{"cath_id":"2.110.10.10","chopping":"516-702","consensus_level":"high","plddt":87.7814,"start":516,"end":702}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P14780","model_url":"https://alphafold.ebi.ac.uk/files/AF-P14780-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P14780-F1-predicted_aligned_error_v6.png","plddt_mean":82.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MMP9","jax_strain_url":"https://www.jax.org/strain/search?query=MMP9"},"sequence":{"accession":"P14780","fasta_url":"https://rest.uniprot.org/uniprotkb/P14780.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P14780/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P14780"}},"corpus_meta":[{"pmid":"26525923","id":"PMC_26525923","title":"MMP-9 in translation: from molecule to brain physiology, pathology, and therapy.","date":"2016","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26525923","citation_count":317,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22519597","id":"PMC_22519597","title":"Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9.","date":"2012","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/22519597","citation_count":139,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34330919","id":"PMC_34330919","title":"Stress-primed secretory autophagy promotes extracellular BDNF maturation by enhancing MMP9 secretion.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34330919","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10474160","id":"PMC_10474160","title":"Expression of Mmp-9 and related matrix metalloproteinase genes during axolotl limb regeneration.","date":"1999","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/10474160","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24752463","id":"PMC_24752463","title":"Glioma-associated microglial MMP9 expression is upregulated by TLR2 signaling and sensitive to minocycline.","date":"2014","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24752463","citation_count":99,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24867100","id":"PMC_24867100","title":"MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24867100","citation_count":98,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16619037","id":"PMC_16619037","title":"Cited2 modulates TGF-beta-mediated upregulation of MMP9.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16619037","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32445177","id":"PMC_32445177","title":"Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival.","date":"2020","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/32445177","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21261731","id":"PMC_21261731","title":"Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer.","date":"2011","source":"Journal of gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/21261731","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26872030","id":"PMC_26872030","title":"The Angiogenic Effect of microRNA-21 Targeting TIMP3 through the Regulation of MMP2 and MMP9.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26872030","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27115178","id":"PMC_27115178","title":"MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma.","date":"2016","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/27115178","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25095981","id":"PMC_25095981","title":"SEMA4b inhibits MMP9 to prevent metastasis of non-small cell lung cancer.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25095981","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25150065","id":"PMC_25150065","title":"Role of MMP2 and MMP9 in TRPV4-induced lung injury.","date":"2014","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25150065","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24621612","id":"PMC_24621612","title":"DLK1 promotes lung cancer cell invasion through upregulation of MMP9 expression depending on Notch signaling.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24621612","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33805901","id":"PMC_33805901","title":"Infarct in the Heart: What's MMP-9 Got to Do with It?","date":"2021","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/33805901","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34801352","id":"PMC_34801352","title":"Dendrobine attenuates osteoclast differentiation through modulating ROS/NFATc1/ MMP9 pathway and prevents inflammatory bone destruction.","date":"2021","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34801352","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32943603","id":"PMC_32943603","title":"Matrix metalloproteinase 9 (MMP9) limits reactive oxygen species (ROS) accumulation and DNA damage in colitis-associated cancer.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32943603","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31754182","id":"PMC_31754182","title":"Tenascin-cmediated vasculogenic mimicry formation via regulation of MMP2/MMP9 in glioma.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31754182","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30653976","id":"PMC_30653976","title":"Macrophage-secreted TSLP and MMP9 promote bleomycin-induced pulmonary fibrosis.","date":"2019","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30653976","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25821815","id":"PMC_25821815","title":"Expression of MMP-9 and VEGF in meningiomas and their correlation with peritumoral brain edema.","date":"2015","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/25821815","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32809114","id":"PMC_32809114","title":"Macrophage-secreted MMP9 induces mesenchymal transition in pancreatic cancer cells via PAR1 activation.","date":"2020","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/32809114","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33246160","id":"PMC_33246160","title":"MMP-9 mediated Syndecan-4 shedding correlates with osteoarthritis severity.","date":"2020","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/33246160","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34093860","id":"PMC_34093860","title":"Tanshinone I, a new EZH2 inhibitor restricts normal and malignant hematopoiesis through upregulation of MMP9 and ABCG2.","date":"2021","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/34093860","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28158191","id":"PMC_28158191","title":"ATP6V1H Deficiency Impairs Bone Development through Activation of MMP9 and MMP13.","date":"2017","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28158191","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25848038","id":"PMC_25848038","title":"Endothelin-1 critically influences cardiac function via superoxide-MMP9 cascade.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25848038","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12062817","id":"PMC_12062817","title":"Control of MMP-9 expression at the maternal-fetal interface.","date":"2002","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12062817","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28961241","id":"PMC_28961241","title":"Synergistic effect of collagenase-1 (MMP1), stromelysin-1 (MMP3) and gelatinase-B (MMP9) gene polymorphisms in breast cancer.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28961241","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39613801","id":"PMC_39613801","title":"The dysadherin/MMP9 axis modifies the extracellular matrix to accelerate colorectal cancer progression.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39613801","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24664993","id":"PMC_24664993","title":"CRKL promotes lung cancer cell invasion through ERK-MMP9 pathway.","date":"2014","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/24664993","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24865997","id":"PMC_24865997","title":"Ablation of MMP9 gene ameliorates paracellular permeability and fibrinogen-amyloid beta complex formation during hyperhomocysteinemia.","date":"2014","source":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24865997","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23076139","id":"PMC_23076139","title":"MMP-9 and uPAR regulated glioma cell migration.","date":"2012","source":"Cell adhesion & migration","url":"https://pubmed.ncbi.nlm.nih.gov/23076139","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28687781","id":"PMC_28687781","title":"P2X7 receptor antagonism modulates IL-1β and MMP9 in human atherosclerotic vessels.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28687781","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32655131","id":"PMC_32655131","title":"Targeting the MAPK7/MMP9 axis for metastasis in primary bone cancer.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32655131","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27573865","id":"PMC_27573865","title":"HOXC6 promotes gastric cancer cell invasion by upregulating the expression of MMP9.","date":"2016","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/27573865","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39386223","id":"PMC_39386223","title":"MMP-9 responsive hydrogel promotes diabetic wound healing by suppressing ferroptosis of endothelial cells.","date":"2024","source":"Bioactive materials","url":"https://pubmed.ncbi.nlm.nih.gov/39386223","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32904569","id":"PMC_32904569","title":"USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32904569","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30587964","id":"PMC_30587964","title":"Cigarette smoke-induced RANKL expression enhances MMP-9 production by alveolar macrophages.","date":"2018","source":"International journal of chronic obstructive pulmonary disease","url":"https://pubmed.ncbi.nlm.nih.gov/30587964","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24526468","id":"PMC_24526468","title":"Anti-inflammatory macrophages activate invasion in pancreatic adenocarcinoma by increasing the MMP9 and ADAM8 expression.","date":"2014","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24526468","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33468174","id":"PMC_33468174","title":"Elevated expression of MMP8 and MMP9 contributes to diabetic osteoarthritis progression in a rat model.","date":"2021","source":"Journal of orthopaedic surgery and research","url":"https://pubmed.ncbi.nlm.nih.gov/33468174","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23292863","id":"PMC_23292863","title":"CD147, MMP9 expression and clinical significance of basal-like breast cancer.","date":"2013","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23292863","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28669039","id":"PMC_28669039","title":"Blockade of MMP-2 and MMP-9 inhibits corneal lymphangiogenesis.","date":"2017","source":"Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","url":"https://pubmed.ncbi.nlm.nih.gov/28669039","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34532475","id":"PMC_34532475","title":"TPM3 mediates epithelial-mesenchymal transition in esophageal cancer via MMP2/MMP9.","date":"2021","source":"Annals of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34532475","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26323669","id":"PMC_26323669","title":"ADAM15 targets MMP9 activity to promote lung cancer cell invasion.","date":"2015","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/26323669","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33450490","id":"PMC_33450490","title":"Muscone derivative ZM-32 inhibits breast tumor angiogenesis by suppressing HuR-mediated VEGF and MMP9 expression.","date":"2021","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/33450490","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26549219","id":"PMC_26549219","title":"DNA Methylation of MMP9 Is Associated with High Levels of MMP-9 Messenger RNA in Periapical Inflammatory Lesions.","date":"2015","source":"Journal of endodontics","url":"https://pubmed.ncbi.nlm.nih.gov/26549219","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21195432","id":"PMC_21195432","title":"Polymorphisms in MMP-9 and TIMP-2 in Chinese patients with varicose veins.","date":"2010","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/21195432","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31366234","id":"PMC_31366234","title":"Induction of ALP and MMP9 activity facilitates invasive behavior in heterogeneous human BMSC and HNSCC 3D spheroids.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31366234","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22121096","id":"PMC_22121096","title":"MMP9 expression in oesophageal adenocarcinoma is upregulated with visceral obesity and is associated with poor tumour differentiation.","date":"2011","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22121096","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23417766","id":"PMC_23417766","title":"Role of site-specific DNA demethylation in TNFα-induced MMP9 expression in keratinocytes.","date":"2013","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/23417766","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28237042","id":"PMC_28237042","title":"Expression of NGF, GDNF and MMP-9 in prostate carcinoma.","date":"2017","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/28237042","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33249185","id":"PMC_33249185","title":"L-theanine suppresses the metastasis of prostate cancer by downregulating MMP9 and Snail.","date":"2020","source":"The Journal of nutritional biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33249185","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17643435","id":"PMC_17643435","title":"Cholesterol inhibits MMP-9 expression in human epidermal keratinocytes and HaCaT cells.","date":"2007","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/17643435","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25600809","id":"PMC_25600809","title":"Cadmium exposure inhibits MMP2 and MMP9 activities in the prostate and testis.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25600809","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26707073","id":"PMC_26707073","title":"CD151 knockdown inhibits osteosarcoma metastasis through the GSK-3β/β-catenin/MMP9 pathway.","date":"2015","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/26707073","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22489798","id":"PMC_22489798","title":"VEGF and MMP-9: biomarkers for canine lymphoma.","date":"2012","source":"Veterinary and comparative oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22489798","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37753805","id":"PMC_37753805","title":"A protein complex of LCN2, LOXL2 and MMP9 facilitates tumour metastasis in oesophageal cancer.","date":"2023","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37753805","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25545756","id":"PMC_25545756","title":"Dual-Functions of miR-373 and miR-520c by Differently Regulating the Activities of MMP2 and MMP9.","date":"2015","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25545756","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17367869","id":"PMC_17367869","title":"Fetal MMP2/MMP9 polymorphisms and intrauterine growth restriction risk.","date":"2007","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17367869","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28904859","id":"PMC_28904859","title":"Sirtuin 6 contributes to migration and invasion of osteosarcoma cells via the ERK1/2/MMP9 pathway.","date":"2017","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/28904859","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33600567","id":"PMC_33600567","title":"Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy.","date":"2021","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/33600567","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36009335","id":"PMC_36009335","title":"Activation and Inhibition of Human Matrix Metalloproteinase-9 (MMP9) by HOCl, Myeloperoxidase and Chloramines.","date":"2022","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/36009335","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28584626","id":"PMC_28584626","title":"MMP2 and MMP9 associate with crescentic glomerulonephritis.","date":"2016","source":"Clinical kidney journal","url":"https://pubmed.ncbi.nlm.nih.gov/28584626","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32209138","id":"PMC_32209138","title":"Expression of RSK4, CD44 and MMP-9 is upregulated and positively correlated in metastatic ccRCC.","date":"2020","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32209138","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33636289","id":"PMC_33636289","title":"PPARγ activation suppresses the expression of MMP9 by downregulating NF-κB post intracerebral hemorrhage.","date":"2021","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/33636289","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23341882","id":"PMC_23341882","title":"ADAM17 mediates MMP9 expression in lung epithelial cells.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23341882","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8978762","id":"PMC_8978762","title":"Reassignment of the 92-kDa type IV collagenase gene (CLG4B) to human chromosome 20.","date":"1996","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8978762","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25441661","id":"PMC_25441661","title":"Increased VEGFR2 and MMP9 protein levels are associated with epithelial dysplasia grading.","date":"2014","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/25441661","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33980872","id":"PMC_33980872","title":"Macrophage morphological plasticity and migration is Rac signalling and MMP9 dependant.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33980872","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22553708","id":"PMC_22553708","title":"Expression of MMP-2 and MMP-9 in retinoblastoma and their significance.","date":"2011","source":"International journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/22553708","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32052443","id":"PMC_32052443","title":"MMP9, CXCR1, TLR6, and MPO participant in the progression of coronary artery disease.","date":"2020","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32052443","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36176311","id":"PMC_36176311","title":"Lactobacilli metabolites restore E-cadherin and suppress MMP9 in cervical cancer cells.","date":"2022","source":"Current research in toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/36176311","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35803110","id":"PMC_35803110","title":"Evaluation of the matrix metalloproteinase 9 (MMP9) inhibitor Andecaliximab as an Anti-invasive therapeutic in Head and neck squamous cell carcinoma.","date":"2022","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35803110","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21802414","id":"PMC_21802414","title":"Concomitant lack of MMP9 and uPA disturbs physiological tissue remodeling.","date":"2011","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/21802414","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31709889","id":"PMC_31709889","title":"Effect of MMP-9 gene knockout on retinal vascular form and function.","date":"2019","source":"Physiological genomics","url":"https://pubmed.ncbi.nlm.nih.gov/31709889","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33629306","id":"PMC_33629306","title":"Expression and clinical significance of MMP-9 and P53 in lung cancer.","date":"2021","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33629306","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32829707","id":"PMC_32829707","title":"Ceramide induces MMP-9 expression through JAK2/STAT3 pathway in airway epithelium.","date":"2020","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/32829707","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30070322","id":"PMC_30070322","title":"MiR-5692a promotes the invasion and metastasis of hepatocellular carcinoma via MMP9.","date":"2018","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30070322","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22237587","id":"PMC_22237587","title":"Association of the MMP9 gene with childhood cedar pollen sensitization and pollinosis.","date":"2012","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22237587","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21488134","id":"PMC_21488134","title":"Gelatinases (MMP2 and MMP9) in swine antral follicle.","date":"2011","source":"BioFactors (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21488134","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33467671","id":"PMC_33467671","title":"MMP-9 Signaling Pathways That Engage Rho GTPases in Brain Plasticity.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33467671","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36609276","id":"PMC_36609276","title":"Fatty acid-binding protein-4 (FABP4) and matrix metalloproteinase-9 (MMP9) as predictive values for nonalcoholic steatohepatitis (NASH).","date":"2023","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/36609276","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35954442","id":"PMC_35954442","title":"Exosomes from EGFR-Mutated Adenocarcinoma Induce a Hybrid EMT and MMP9-Dependant Tumor Invasion.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35954442","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33959010","id":"PMC_33959010","title":"Berberine Regulated miR150-5p to Inhibit P2X7 Receptor, EMMPRIN and MMP-9 Expression in oxLDL Induced Macrophages.","date":"2021","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33959010","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25063292","id":"PMC_25063292","title":"Expression and significance of MMP-9 and MDM2 in the oncogenesis of lung cancer in rats.","date":"2014","source":"Asian Pacific journal of tropical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25063292","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30070315","id":"PMC_30070315","title":"Expression and correlation of MMP-9, VEGF, and p16 in infantile hemangioma.","date":"2018","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30070315","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34607974","id":"PMC_34607974","title":"Computational study of effective matrix metalloproteinase 9 (MMP9) targeting natural inhibitors.","date":"2021","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/34607974","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27633065","id":"PMC_27633065","title":"FoxO3a mediates glioma cell invasion by regulating MMP9 expression.","date":"2016","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/27633065","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28678970","id":"PMC_28678970","title":"Immunohistochemical expression of TGF-β1 and MMP-9 in periapical lesions.","date":"2017","source":"Brazilian oral research","url":"https://pubmed.ncbi.nlm.nih.gov/28678970","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28205286","id":"PMC_28205286","title":"Association of MMP-9 gene polymorphisms with nephrolithiasis patients.","date":"2017","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/28205286","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39252956","id":"PMC_39252956","title":"MMP9 drives ferroptosis by regulating GPX4 and iron signaling.","date":"2024","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/39252956","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25951835","id":"PMC_25951835","title":"Resistance of MMP9 and TIMP1 to endotoxin tolerance.","date":"2014","source":"Pathogens and disease","url":"https://pubmed.ncbi.nlm.nih.gov/25951835","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32266319","id":"PMC_32266319","title":"microRNA-204-5p Participates in Atherosclerosis Via Targeting MMP-9.","date":"2020","source":"Open medicine (Warsaw, Poland)","url":"https://pubmed.ncbi.nlm.nih.gov/32266319","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22395516","id":"PMC_22395516","title":"Collagen IV and MMP-9 expression in hypertrophic gingiva during orthodontic treatment.","date":"2012","source":"Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie","url":"https://pubmed.ncbi.nlm.nih.gov/22395516","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19833395","id":"PMC_19833395","title":"Polyclonal immunoglobulins (IVIg) induce expression of MMP-9 in microglia.","date":"2009","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/19833395","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30689107","id":"PMC_30689107","title":"Density-dependent ERK MAPK expression regulates MMP-9 and influences growth.","date":"2019","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30689107","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36810514","id":"PMC_36810514","title":"Characterization of Active MMP9 in Chronic Inflammatory Diseases Using a Novel Anti-MMP9 Antibody.","date":"2023","source":"Antibodies (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/36810514","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29155140","id":"PMC_29155140","title":"Pregnancy and parturition negatively impact vaginal angle and alter expression of vaginal MMP-9.","date":"2017","source":"American journal of obstetrics and gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/29155140","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31392078","id":"PMC_31392078","title":"Natriuretic peptide receptor a promotes breast cancer development by upregulating MMP9.","date":"2019","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31392078","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36737785","id":"PMC_36737785","title":"Hydrogen attenuates postoperative pain through Trx1/ASK1/MMP9 signaling pathway.","date":"2023","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/36737785","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38212502","id":"PMC_38212502","title":"Isorhamnetin Downregulates MMP2 and MMP9 to Inhibit Development of Rheumatoid Arthritis through SRC/ERK/CREB Pathway.","date":"2024","source":"Chinese journal of integrative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38212502","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23128233","id":"PMC_23128233","title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/23128233","citation_count":3725,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10419448","id":"PMC_10419448","title":"Matrix metalloproteinases.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10419448","citation_count":3561,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10652271","id":"PMC_10652271","title":"Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis.","date":"2000","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/10652271","citation_count":1558,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9590175","id":"PMC_9590175","title":"MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes.","date":"1998","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9590175","citation_count":1455,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12062105","id":"PMC_12062105","title":"Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand.","date":"2002","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/12062105","citation_count":1354,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33419373","id":"PMC_33419373","title":"The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33419373","citation_count":1233,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2551898","id":"PMC_2551898","title":"SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages.","date":"1989","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2551898","citation_count":1079,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11081634","id":"PMC_11081634","title":"MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis.","date":"2000","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/11081634","citation_count":1076,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12208863","id":"PMC_12208863","title":"Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms.","date":"2002","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/12208863","citation_count":891,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12398893","id":"PMC_12398893","title":"MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis.","date":"2002","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/12398893","citation_count":713,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8426746","id":"PMC_8426746","title":"Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells.","date":"1993","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8426746","citation_count":712,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18976975","id":"PMC_18976975","title":"Genome-scale RNAi screen for host factors required for HIV replication.","date":"2008","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/18976975","citation_count":627,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23547785","id":"PMC_23547785","title":"Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade.","date":"2013","source":"Critical reviews in biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23547785","citation_count":622,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12668489","id":"PMC_12668489","title":"Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease.","date":"2003","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/12668489","citation_count":612,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11486009","id":"PMC_11486009","title":"The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11486009","citation_count":579,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1371271","id":"PMC_1371271","title":"Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1371271","citation_count":566,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11023497","id":"PMC_11023497","title":"Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11023497","citation_count":546,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12865405","id":"PMC_12865405","title":"HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver.","date":"2003","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/12865405","citation_count":502,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18077379","id":"PMC_18077379","title":"Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18077379","citation_count":488,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11839588","id":"PMC_11839588","title":"Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells.","date":"2002","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11839588","citation_count":470,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18323498","id":"PMC_18323498","title":"MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke.","date":"2008","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/18323498","citation_count":469,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1400481","id":"PMC_1400481","title":"Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1400481","citation_count":460,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9789069","id":"PMC_9789069","title":"Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9789069","citation_count":405,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12960961","id":"PMC_12960961","title":"Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator.","date":"2003","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12960961","citation_count":384,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11606713","id":"PMC_11606713","title":"Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11606713","citation_count":380,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51525,"output_tokens":6935,"usd":0.1293},"stage2":{"model":"claude-opus-4-6","input_tokens":10673,"output_tokens":3841,"usd":0.224085},"total_usd":0.808548,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":65872,"output_tokens":10716,"usd":0.179178},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":14938,"output_tokens":4372,"usd":0.275985}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2022,\n      \"finding\": \"HOCl generated by myeloperoxidase (MPO) activates proMMP9 by oxidizing the cysteine residue in the prodomain (the 'cysteine-switch' mechanism), and low concentrations of chloramines formed from HOCl reacting with amino acids, albumin, and ECM proteins (laminin, fibronectin, basement membrane extracts) also activate proMMP9; high HOCl concentrations inactivate active MMP9.\",\n      \"method\": \"Fluorescence-activity assays, gel zymography, enzymatic MPO/H2O2/Cl- system, competitive inhibition with methionine\",\n      \"journal\": \"Antioxidants (Basel, Switzerland)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic reconstitution with multiple substrates, mechanistic mutagenesis-equivalent (competitive inhibition), replicated across multiple chloramine species\",\n      \"pmids\": [\"36009335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Active MMP9 (but not a catalytically inactive construct) interacts with GPX4 and glutathione reductase, reducing GPX4 expression and activity, suppresses key transcription factors (SP1, CREB1, NRF2, FOXO3, ATF4) alongside GPX1 and FSP1, and regulates iron metabolism by modulating iron import, storage, and export, thereby driving ferroptosis; LC-MS/MS identified 83 MMP9-interacting proteins at subcellular levels.\",\n      \"method\": \"MMP9 construct without collagenase activity (domain mutant), LC-MS/MS interactome, western blot, integrated pathway analysis\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — domain mutant construct + MS interactome in single study; novel finding not yet independently replicated\",\n      \"pmids\": [\"39252956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Glucocorticoid-mediated stress enhances secretory autophagy via the stress-responsive co-chaperone FKBP51, leading to secretion of MMP9, which in turn cleaves pro-BDNF to its mature form (mBDNF) extracellularly, as confirmed by cellular assays and in vivo microdialysis.\",\n      \"method\": \"Secretory autophagy pathway manipulation, cellular assays, in vivo microdialysis, proteomic identification of MMP9 in secretome\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (secretomics, in vivo microdialysis, cellular cleavage assays) in single study; direct substrate identification\",\n      \"pmids\": [\"34330919\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Macrophage-secreted MMP9 acts as a PAR1 agonist in pancreatic ductal adenocarcinoma (PDAC) cells by cleaving PAR1, inducing mesenchymal transition; PAR1 and/or MMP9 inhibition blocked macrophage-driven mesenchymal transition, and protease profiling identified MMP9 as the relevant PAR1-activating protease.\",\n      \"method\": \"Medium transfer experiments, PAR1 cleavage assays, specific inhibitors of MMP9 and PAR1, recombinant agonist rescue, siRNA knockdown\",\n      \"journal\": \"Cellular oncology (Dordrecht, Netherlands)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — PAR1 cleavage assay identifies MMP9 as the protease, validated with specific inhibitors and siRNA knockdown across multiple orthogonal experiments\",\n      \"pmids\": [\"32809114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MMP9 mediates shedding of Syndecan-4 (Sdc4) in osteoarthritis; MMP-9 inhibition and siRNA knockdown of MMP9 decreased Sdc4 shedding in vitro, and shed Sdc4 correlated with MMP9 levels in synovial fluid; increased Sdc4 shedding desensitized chondrocytes to IL-1β signaling via reduced ERK phosphorylation.\",\n      \"method\": \"ELISA, siRNA knockdown, MMP inhibitor treatment, western blot (pERK/ERK), clinical sample correlation\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA knockdown and pharmacological inhibition both confirm MMP9 as Sdc4 sheddase; functional consequence (ERK signaling) measured\",\n      \"pmids\": [\"33246160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Endothelin-1 controls MMP9 expression via a superoxide-dependent cascade in the heart; genetic absence of Mmp9 improved cardiac function in endothelin-1 hypomorphic mice, and a superoxide dismutase mimetic reduced Mmp9 overexpression and substantially improved cardiac function, placing superoxide upstream of Mmp9.\",\n      \"method\": \"Genetic mouse models (Edn1 hypomorphs, Mmp9 knockout), superoxide dismutase mimetic treatment, epistasis analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with multiple alleles (Edn1 hypomorph + Mmp9 KO double mutant) plus pharmacological confirmation; replicated across multiple model combinations\",\n      \"pmids\": [\"25848038\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Cited2 physically associates with Smad2 and Smad3 (confirmed by co-IP, mammalian two-hybrid, and GST-pulldown) and, together with p300, is recruited to the MMP9 promoter upon TGF-β stimulation, enhancing TGF-β-mediated transcriptional upregulation of MMP9; Cited2 knockdown in MDA-MB-231 cells attenuated TGF-β-mediated MMP9 upregulation and cell invasion.\",\n      \"method\": \"Co-immunoprecipitation, mammalian two-hybrid, GST-pulldown, chromatin immunoprecipitation, luciferase reporter assay, siRNA knockdown, Matrigel invasion assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal binding assays plus ChIP demonstrating promoter occupancy, functional validation by knockdown\",\n      \"pmids\": [\"16619037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TRPV4 channel activation provides calcium required for activation of MMP2 and MMP9 in the intact lung; pharmacological blockade of MMP2/9 (SB-3CT) protected against TRPV4-induced lung injury; TRPV4 activation also decreased TIMP2 levels, increasing availability of active MMPs.\",\n      \"method\": \"TRPV4 agonist (GSK-1016790A) perfusion in TRPV4+/+ vs TRPV4-/- mouse lungs, Western blot for active MMP isoforms, SB-3CT pharmacological blockade, lung injury endpoints (wet-to-dry weight, BAL protein)\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic (TRPV4 KO) and pharmacological (SB-3CT) approaches converge to place TRPV4-Ca2+ upstream of MMP9 activation\",\n      \"pmids\": [\"25150065\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ADAM15 proteolytically cleaves and activates pro-MMP9 in vitro and interacts with MMP9 in vivo; ADAM15 also upregulates MMP9 expression via the MEK-ERK pathway; MMP9 knockdown attenuated ADAM15-promoted lung cancer cell invasion.\",\n      \"method\": \"In vitro pro-MMP9 cleavage assay, co-immunoprecipitation (in vivo interaction), MEK inhibitor, shRNA knockdown of MMP9, Matrigel invasion assay\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro protease cleavage assay establishes direct activation of pro-MMP9 by ADAM15; supported by co-IP and functional rescue\",\n      \"pmids\": [\"26323669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Concomitant genetic deficiency of MMP9 and uPA (but not tPA) severely impairs gestation, bone growth, and cutaneous wound healing in mice; uPA-deficiency additionally exacerbated MMP9-deficiency phenotypes, and compensatory upregulation of uPA activity was observed in MMP9-deficient wounds, establishing functional epistasis between MMP9 and uPA.\",\n      \"method\": \"Double-knockout mouse models (Mmp9-/- x uPA-/-, Mmp9-/- x tPA-/-, Mmp9-/- x uPAR-/-), wound healing assays, bone growth analysis, uPA activity measurement\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean double-KO genetic epistasis across multiple biological processes; multiple allele combinations tested\",\n      \"pmids\": [\"21802414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Hyperhomocysteinemia (HHcy) causes MMP9-dependent cerebrovascular permeability increase by downregulating VE-cadherin (paracellular pathway), leading to enhanced fibrinogen-Aβ complex formation; these effects were ameliorated in Cbs+/-/Mmp9-/- double-knockout mice, establishing MMP9 in this pathway.\",\n      \"method\": \"Double-knockout mice (Cbs+/-/Mmp9-/-), dual-tracer cerebrovascular permeability assay, immunohistochemistry for VE-cadherin and Fg-Aβ complex, novel object recognition test\",\n      \"journal\": \"Journal of cerebral blood flow and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis (double KO) with quantitative permeability assay and identified downstream substrate (VE-cadherin)\",\n      \"pmids\": [\"24865997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TLR2/6 signaling mediates glioma-induced upregulation of MMP9 in microglia; glioma supernatant induced MMP9 expression and TLR2 upregulation in microglia; TLR2-deficient mice showed attenuated microglial MMP9 upregulation; p38 MAPK antagonism and minocycline inhibited both MMP9 and TLR2 upregulation.\",\n      \"method\": \"TLR-deficient mouse models, in vitro microglial cultures with glioma conditioned medium, p38 MAPK inhibitor, experimental mouse glioma model\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic (TLR2 KO) and pharmacological epistasis converge; validated in both in vitro and in vivo glioma models\",\n      \"pmids\": [\"24752463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In zebrafish, MMP9 (and Rac GTPase signaling) is required for mesenchymal-mode macrophage migration through ECM and for hematopoietic stem/progenitor cell (HSPC) mobilization; MMP inhibitor treatment abolished ECM degradation and HSPC mobilization while differently affecting macrophage morphology.\",\n      \"method\": \"Live imaging in zebrafish embryo, MMP inhibitor treatment, Rac GTPase inhibitor, morphometric analysis of macrophage shapes, HSPC mobilization functional readout\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — live imaging with pharmacological inhibition in physiological context; zebrafish ortholog study with defined functional readout\",\n      \"pmids\": [\"33980872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Dysadherin directly targets MMP9, and the dysadherin/MMP9 axis enhances CRC cell invasiveness and ECM proteolytic activity, activates cancer-associated fibroblasts, and remodels the ECM; MMP9 overexpression reversed the effects of dysadherin knockout, establishing MMP9 as the downstream effector.\",\n      \"method\": \"Co-immunoprecipitation (direct protein-protein interaction), dysadherin knockout mouse models, humanized mouse model, MMP9 overexpression rescue, in vitro invasion assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct binding assay (Co-IP) plus genetic rescue (KO reversed by MMP9 OE) in multiple model systems\",\n      \"pmids\": [\"39613801\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"LCN2, LOXL2, and MMP9 form a ternary protein complex; LCN2-MMP9 and LCN2-LOXL2 interactions occur both intracellularly and extracellularly, while LOXL2-MMP9 interaction only occurs intracellularly; the ternary complex enhances fibronectin and Matrigel degradation, filopodia formation, and activates FAK/AKT/GSK3β signaling.\",\n      \"method\": \"Protein-protein interaction assays (Co-IP pulldown), in vitro degradation assays (fibronectin, Matrigel), confocal microscopy for filopodia, in vivo tumor growth assays, western blot signaling\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal interaction assays with subcellular localization distinction; functional consequence validated in vitro and in vivo\",\n      \"pmids\": [\"37753805\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In macrophages treated with oxLDL, EMMPRIN and MMP9 expression is regulated downstream of P2X7 receptor via the AMPK-α/MAPK (JNK, p38, ERK) pathway; P2X7R inhibition (A-438079) decreased both EMMPRIN and MMP9; berberine upregulated miR150-5p to decrease P2X7R expression, thereby suppressing MMP9.\",\n      \"method\": \"P2X7R inhibitor (A-438079), AMPK-α/MAPK western blot, miR150-5p mimic transfection, ELISA for MMP9\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — pathway inhibition experiments in a single cell model; mechanistic pathway placement without genetic validation\",\n      \"pmids\": [\"33959010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"LPS-induced MMP9 expression in lung epithelial cells (A549) is mediated through the ADAM17→TNF-α→TNFR1→NF-κB signaling cascade; lentiviral RNAi knockdown of ADAM17 inhibited TNF-α production, IκBα phosphorylation, p65 activation, and downstream MMP9 expression.\",\n      \"method\": \"Lentivirus-mediated RNAi (ADAM17), NF-κB inhibitor (PDTC), TNFR1 blocking peptide, western blot for IκBα/p65 phosphorylation, MMP9 quantification\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — lentiviral RNAi plus pharmacological inhibitors at multiple pathway nodes in a single study\",\n      \"pmids\": [\"23341882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PPARγ activation suppresses MMP9 expression post-intracerebral hemorrhage by inhibiting NF-κB; direct interactions of NF-κB with PPARγ and with the MMP9 gene were confirmed by protein co-immunoprecipitation and chromatin immunoprecipitation respectively; NF-κB inhibition alone also suppressed MMP9.\",\n      \"method\": \"PPARγ agonist (rosiglitazone) and antagonist (GW9662) in vivo/in vitro, NF-κB inhibitor (JSH-23), co-immunoprecipitation of NF-κB/PPARγ, chromatin immunoprecipitation of NF-κB at MMP9 gene, western blot\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP directly links NF-κB to MMP9 promoter; co-IP confirms PPARγ-NF-κB interaction; convergent pharmacological and molecular evidence\",\n      \"pmids\": [\"33636289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The simultaneous targeting of both the MMP9 catalytic domain (via engineered N-TIMP2 variant C9) and the MMP9 hemopexin domain (PEX)/CD44 interface by a bi-functional inhibitor (C9-PEX) reduces MMP9 catalytic activity, MMP9 cellular levels, MMP9 homodimerization, and downstream MAPK/ERK pathway signaling; CD44 is cleaved by the MMP9 catalytic domain and interacts with MMP9 through its hemopexin domain.\",\n      \"method\": \"Yeast surface display engineering, in vitro inhibition assays, cell-based invasion assays, MAPK/ERK pathway western blot\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — engineered domain-specific inhibitors validate distinct functional domains of MMP9; both catalytic and PEX domain functions tested\",\n      \"pmids\": [\"33600567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MMP9 limits reactive oxygen species accumulation and DNA damage in colitis-associated cancer (CAC) via a 'MMP9-Notch1-ARF-p53 axis' tumor suppressor pathway; transgenic colonic epithelial MMP9 expression (TgM9) reduced ROS, DNA damage, and increased mismatch repair gene expression; MMP9 siRNA nanoparticles reversed these effects.\",\n      \"method\": \"TgM9 transgenic mice, MMP9 siRNA nanoparticles (proof of concept), ROS measurement, DNA damage assays, mismatch repair gene expression analysis in CAC model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic gain-of-function plus nanoparticle-mediated loss-of-function with multiple molecular readouts; single lab\",\n      \"pmids\": [\"32943603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The MMP9 gene (CLG4B, 92-kDa type IV collagenase) was remapped to human chromosome 20 (not chromosome 16 as previously assigned), based on somatic cell hybrid panel screening, FISH, and linkage analysis with a newly identified polymorphism.\",\n      \"method\": \"Somatic cell hybrid panel, fluorescence in situ hybridization (FISH), linkage analysis\",\n      \"journal\": \"Cytogenetics and cell genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — three independent orthogonal methods (somatic cell hybrid, FISH, linkage) converge on chromosomal assignment\",\n      \"pmids\": [\"8978762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TNFα-induced MMP9 expression in keratinocytes is accompanied by site-specific DNA demethylation at the −36 bp CpG site in the MMP9 promoter; the demethylated −36 bp site confers higher transcriptional activity in dual-luciferase reporter assays, establishing an epigenetic mechanism for persistent MMP9 upregulation.\",\n      \"method\": \"Bisulfite sequencing PCR, methylation-specific PCR, dual-luciferase reporter assay, TNFα stimulation of HaCaT keratinocytes\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bisulfite sequencing identifies specific CpG; reporter assay validates functional consequence of methylation state at identified site\",\n      \"pmids\": [\"23417766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MMP9 expression is downstream of the MAPK7 (ERK5) kinase in primary bone cancer; MAPK7 knockdown by RNAi reduces MMP9 expression alongside IL1B, IL6, IL8, and mesenchymal markers, and decreases lung metastasis in xenograft models.\",\n      \"method\": \"RNA interference knockdown of MAPK7, RNA-seq, cell line migration/colony assays, xenograft mouse models, single-cell RNA-sequencing\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RNAi with transcriptomic and in vivo validation; single lab but multiple readouts\",\n      \"pmids\": [\"32655131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Active MMP9 (F107-MMP9 isoform, the pro-domain-cleaved form) is spatially localized to sites of active tissue remodeling (fistulae, dermal fissures) and is expressed by myeloid cells (macrophages and neutrophils) in inflammatory diseases; the active isoform is distinct from and less abundant than pro-MMP9 in tissue.\",\n      \"method\": \"Novel anti-active-MMP9 antibody (F107), immunohistochemistry on human tissue sections (IBD fistulae, hidradenitis suppurativa), multiple in vitro validation assays\",\n      \"journal\": \"Antibodies (Basel, Switzerland)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — novel isoform-specific antibody with multiple in vitro and tissue validation assays; spatially resolves active vs. pro-MMP9 in disease\",\n      \"pmids\": [\"36810514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NFATc1 nuclear translocation downstream of RANKL/ROS/p38/c-Fos signaling drives MMP9 transcription during osteoclastogenesis; dendrobine inhibited RANKL-induced ROS, p-p38, c-Fos and NFATc1 nuclear translocation, dramatically reducing MMP9 mRNA and protein in osteoclasts.\",\n      \"method\": \"BMM and RAW264.7 osteoclast differentiation assays, ROS measurement, western blot for NFATc1/p-p38/c-Fos, qPCR for MMP9, in vivo LPS osteolysis model\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple signaling nodes interrogated with pharmacological inhibitor; pathway hierarchy established in both in vitro and in vivo models\",\n      \"pmids\": [\"34801352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"MMP9 inhibition by the broad-spectrum invadopodia inhibitor marimastat (but not the selective MMP9 inhibitor andecaliximab/ADX) blocks HNSCC invadopodia-based matrix degradation and tumor spheroid invasion, indicating that MMP9 alone is insufficient to account for invadopodia function and that redundant MMPs contribute.\",\n      \"method\": \"MMP9 inhibitor ADX and broad-spectrum MMP inhibitor marimastat, HNSCC invadopodia ECM degradation assays (confocal), tumor spheroid invasion, organotypic cultures with CAFs\",\n      \"journal\": \"Oral oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — comparative pharmacological inhibition with defined functional assays; reveals limits of MMP9 specificity in invasion\",\n      \"pmids\": [\"35803110\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MMP9 (gelatinase B) is secreted as an inactive zymogen and activated extracellularly by proteolytic removal of its prodomain cysteine-switch, including via HOCl/myeloperoxidase-dependent oxidation and by proteases such as ADAM15; active MMP9 degrades ECM components (including type IV collagen, fibronectin), cleaves cell-surface substrates such as CD44, Syndecan-4, and PAR1 (inducing downstream signaling), processes proBDNF to mature BDNF, and modulates ferroptosis by interacting with and suppressing GPX4; its transcription is controlled by NF-κB, NFATc1, Smad3/Cited2/p300, and site-specific promoter demethylation, with upstream regulators including endothelin-1/superoxide, TRPV4-Ca²⁺, MAPK7/ERK, and TLR2/6, while its activity is opposed by TIMPs and endotoxin tolerance; MMP9 plays defined roles in synaptic plasticity, neuroinflammation, cardiac remodeling, bone resorption, wound healing, and tumor invasion.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"MMP9 (92-kDa type IV collagenase/gelatinase B) was first characterized as a metalloprotease secreted by SV40-transformed human lung fibroblasts, normal human alveolar macrophages, monocytic U937 cells, fibrosarcoma HT1080 cells, and keratinocytes. The preproenzyme (predicted Mr 78,426) contains a 19-amino-acid signal peptide and is secreted as a 92-kDa glycosylated proenzyme. It forms a noncovalent complex with TIMP and can be activated by organomercurials, resulting in removal of 73 amino acids from the NH2-terminus. The active enzyme degrades native types IV and V collagen. Five domains were identified: amino-terminal, zinc-binding, fibronectin-like collagen-binding, carboxyl-terminal hemopexin-like, and a unique proline-rich domain homologous to alpha2(V) collagen.\",\n      \"method\": \"Protein purification, NH2-terminal sequencing, substrate digestion assays, inhibitor complex analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original biochemical characterization with purification, sequencing, and functional assays\",\n      \"pmids\": [\"2551898\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"MMP-3 (stromelysin) activates proMMP-9 through a stepwise mechanism: MMP-3 first cleaves proMMP-9 at the Glu40-Met41 bond in the propeptide to generate an 86-kDa intermediate, then cleaves Arg87-Phe88 to yield an active 82-kDa form. This was the first demonstration of zymogen activation of one MMP family member by another.\",\n      \"method\": \"In vitro activation assay, NH2-terminal sequencing, alpha2-macroglobulin binding studies\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with site-specific cleavage site identification\",\n      \"pmids\": [\"1371271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"ProMMP-9 purified from HT1080 fibrosarcoma cells can be activated by 4-aminophenylmercuric acetate (yielding Mr 83,000 intermediate then Mr 67,000 active form), as well as by cathepsin G, trypsin, alpha-chymotrypsin, and MMP-3 (stromelysin 1), but not by plasmin, leukocyte elastase, plasma kallikrein, thrombin, or MMP-1. HOCl partially activates the zymogen. TIMP-1 complexed with proMMP-9 inhibits conversion of the intermediate to the active species. Active MMP-9 degrades type I gelatin rapidly and also cleaves native collagens (alpha2 chain of type I, types III, IV, and V) at non-denaturing temperatures.\",\n      \"method\": \"Protein purification, activation assays, immunoblot, substrate digestion assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — comprehensive in vitro enzyme characterization with multiple activators and substrates\",\n      \"pmids\": [\"1400481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The MMP9 gene promoter contains three functionally important motifs — AP-1, NF-κB, and Sp-1 binding sites — that positively contribute to induction by TPA and TNFα. The AP-1 site is indispensable but requires synergistic cooperation with either the NF-κB or Sp-1 site for full induction. TNFα rapidly induces nuclear factors binding to AP-1 and κB elements in OST cells.\",\n      \"method\": \"Promoter deletion/mutation analysis with luciferase reporter, EMSA/nuclear factor binding assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — deletion and mutation analysis of promoter elements with functional reporter assays\",\n      \"pmids\": [\"8426746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. In MMP-9-null mice, apoptosis, vascularization, and ossification in the growth plate are delayed, causing progressive growth plate lengthening (~8x normal). Bone marrow transplantation with wild-type cells rescues vascularization and ossification, identifying bone-marrow-derived 'chondroclasts' as the relevant MMP-9-expressing cell population. Growth plates from null mice show delayed release of an angiogenic activator in culture, establishing MMP-9 as a controller of angiogenesis.\",\n      \"method\": \"Gene knockout (null mutation), bone marrow transplantation rescue, histology, in vitro organ culture\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with rescue experiment, multiple orthogonal readouts\",\n      \"pmids\": [\"9590175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"RECK, a membrane-anchored glycoprotein with EGF-like repeats and serine-protease inhibitor-like domains, suppresses MMP-9 secretion in malignant cells and directly binds to and inhibits MMP-9 proteolytic activity. Restored RECK expression in malignant cells reduces MMP-9 secretion and invasive activity.\",\n      \"method\": \"cDNA expression screening, invasion assay, purified protein binding and inhibition assays, conditioned medium analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — purified protein interaction and inhibition assay combined with cellular rescue\",\n      \"pmids\": [\"9789069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CD44 provides a cell surface docking receptor for proteolytically active MMP-9, and cell surface localization of MMP-9 (via CD44) is required for its ability to promote tumor invasion and angiogenesis. MMP-9 (and MMP-2) proteolytically cleave latent TGF-beta, providing a novel mechanism for TGF-beta activation. MMP-9 localization to normal keratinocyte surfaces is also CD44-dependent and can activate latent TGF-beta.\",\n      \"method\": \"Co-immunoprecipitation, cell surface localization assays, in vitro TGF-beta cleavage assay, tumor invasion and angiogenesis models\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — biochemical cleavage assay, receptor-ligand interaction, and functional cellular assays\",\n      \"pmids\": [\"10652271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"MMP-9 is predominantly expressed by inflammatory cells (neutrophils, macrophages, mast cells) rather than by neoplastic keratinocytes in a mouse model of multistage skin carcinogenesis driven by HPV16. MMP-9-null transgenic mice show reduced keratinocyte hyperproliferation at all neoplastic stages and decreased incidence of invasive tumors. Bone marrow chimeras expressing MMP-9 only in hematopoietic cells reconstitute MMP-9-dependent contributions to carcinogenesis, establishing that inflammatory cell-derived MMP-9 promotes tumor progression.\",\n      \"method\": \"Transgenic knockout mouse, bone marrow transplantation chimeras, histopathology, tumor incidence analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout combined with bone marrow chimera rescue in vivo\",\n      \"pmids\": [\"11081634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"MMP-9 (neutrophil gelatinase B) cleaves IL-8(1-77) at the aminoterminus to generate IL-8(7-77), resulting in a 10- to 27-fold higher potency in neutrophil activation (intracellular Ca2+ increase, gelatinase B secretion, chemotaxis). This enhancement correlates with increased binding to neutrophils and enhanced signaling through CXCR1 but not CXCR2. MMP-9 also degrades CTAP-III, PF-4, and GRO-alpha but leaves RANTES and MCP-2 intact, demonstrating substrate specificity for CXC chemokine processing.\",\n      \"method\": \"In vitro enzyme cleavage assays, calcium flux assay, chemotaxis assay, receptor binding assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro cleavage with biochemical characterization and multiple functional readouts\",\n      \"pmids\": [\"11023497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"MMP-9 and NGAL (neutrophil gelatinase-associated lipocalin) form a ~125-kDa complex detectable in urine. NGAL protects MMP-9 from degradation in a dose-dependent manner, thereby preserving MMP-9 enzymatic activity. The complex can be reconstituted in vitro by mixing recombinant MMP-9 and NGAL.\",\n      \"method\": \"Substrate gel electrophoresis, immunoprecipitation, Western blot, in vitro reconstitution, cell culture overexpression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — complex identified by multiple biochemical approaches and reconstituted in vitro\",\n      \"pmids\": [\"11486009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Thrombospondin-1 (TSP1) suppresses in vivo activation of proMMP-9 and in vitro enzymatic activation of proMMP-9 is suppressed by purified TSP1. Absence of TSP1 in mammary tumor-prone mice results in higher levels of active MMP-9 and increased VEGF/VEGFR2 association, implicating TSP1 as an endogenous regulator of MMP-9 activation.\",\n      \"method\": \"Transgenic mouse model (TSP1 knockout and overexpression), in vitro proMMP9 activation assay with purified TSP1, VEGFR2 co-precipitation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — in vitro inhibition assay with purified proteins combined with in vivo genetic model\",\n      \"pmids\": [\"11606713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"MMP-9 induced in bone marrow (BM) cells releases soluble Kit-ligand (sKitL) from the bone marrow niche, enabling transfer of hematopoietic and endothelial stem cells from quiescent to proliferative niches. BM ablation induces SDF-1, which upregulates MMP-9 expression, causing shedding of sKitL and recruitment of c-Kit+ stem/progenitors. In MMP-9-/- mice, sKitL release and HSC motility are impaired; exogenous sKitL restores hematopoiesis and survival.\",\n      \"method\": \"MMP-9 knockout mice, BM ablation, SDF-1 stimulation, exogenous sKitL rescue, stem cell mobilization assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with molecular rescue, identifies specific substrate (sKitL) shedding mechanism\",\n      \"pmids\": [\"12062105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"MMP-9 and MMP-2 work in concert to produce aortic aneurysms in a mouse model; neither MMP-9KO nor MMP-2KO mice develop aneurysms following CaCl2 application. Reinfusion of wild-type macrophages into MMP-9KO mice reconstitutes AAA formation, but not in MMP-2KO mice, indicating macrophage-derived MMP-9 and mesenchymal cell MMP-2 play distinct and cooperative roles.\",\n      \"method\": \"Genetic knockout mice, experimental AAA induction, macrophage reinfusion rescue experiment\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — double knockout and cell-specific rescue experiment\",\n      \"pmids\": [\"12208863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"MMP-9 and MMP-2 are shed by endothelial cells as components of membrane vesicles (300–600 nm) in both pro- and active forms. Shedding is stimulated by serum and angiogenic factors FGF-2 and VEGF. Shed vesicles stimulate autocrine endothelial cell invasion through Matrigel and cord formation, establishing vesicle-based MMP secretion as a mechanism for focalized proteolytic activity during angiogenesis.\",\n      \"method\": \"Ultrastructural analysis, zymography, Western blot, immunogold labeling, invasion and morphogenesis assays\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods identifying vesicle-associated MMP-9 with functional consequence\",\n      \"pmids\": [\"11839588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"MMP9 is specifically induced in premetastatic lung endothelial cells and macrophages by distant primary tumors via VEGFR-1/Flt-1 tyrosine kinase signaling, and this induction significantly promotes lung-specific metastasis. Deletion of VEGFR-1 TK or MMP9 markedly reduces lung metastasis in mice.\",\n      \"method\": \"Genetic deletion of VEGFR-1 TK and MMP9 in mice, experimental metastasis assays, immunohistochemistry in human samples\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — double genetic approach with in vivo metastasis readout\",\n      \"pmids\": [\"12398893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"tPA upregulates MMP-9 via LRP (low-density lipoprotein receptor-related protein) signaling in brain endothelial cells. RNAi knockdown of LRP abolished tPA-induced MMP-9 upregulation. MMP-9 levels were lower in tPA-knockout mice after focal ischemia, demonstrating that tPA-LRP signaling drives MMP-9-mediated neurovascular matrix degradation in stroke.\",\n      \"method\": \"RNAi knockdown, tPA knockout mice, focal ischemia model, cell culture MMP-9 measurement\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — RNAi epistasis and genetic knockout in vivo\",\n      \"pmids\": [\"12960961\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Hepatic injury induces MMP-9 activity in the liver, which together with SDF-1 and HGF promotes recruitment of human CD34+ hematopoietic progenitors to the liver. MMP-9 activity is induced by irradiation or inflammation and contributes to CXCR4 upregulation and SDF-1-mediated progenitor homing.\",\n      \"method\": \"In vivo mouse liver injury model, MMP-9 activity measurement, CXCR4 neutralization, NOD/SCID engraftment assay\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo model with functional readout but MMP-9's direct substrate in this context not fully defined\",\n      \"pmids\": [\"12865405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Cited2, a CBP/p300-binding transcriptional co-activator, physically associates with Smad2 and Smad3 (confirmed by co-IP, mammalian two-hybrid, and GST pull-down) and enhances TGF-β-mediated upregulation of MMP9. p300 further enhances the Cited2-Smad3 interaction. Chromatin immunoprecipitation showed Cited2 and Smad3 are recruited to the MMP9 promoter upon TGF-β stimulation. Knockdown of Cited2 in MDA-MB-231 cells attenuates TGF-β-mediated MMP9 upregulation and cell invasion.\",\n      \"method\": \"Co-IP, mammalian two-hybrid, GST pull-down, ChIP, luciferase reporter, siRNA knockdown, invasion assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal protein interaction methods combined with ChIP and functional invasion assay\",\n      \"pmids\": [\"16619037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Human neutrophils uniquely release TIMP-free proMMP-9 from their granules, which upon activation is a potent proangiogenic stimulus at subnanogram levels on the chick chorioallantoic membrane. TIMP-1 complexation abolishes the proangiogenic activity of neutrophil proMMP-9, demonstrating that the TIMP-free status and catalytic activity of the activated enzyme are both required for the angiogenic response.\",\n      \"method\": \"Granule purification, in vivo chick CAM angiogenesis assay, stoichiometric TIMP-1 complexation, MMP activity assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — purified protein functional assay in vivo with biochemical characterization of TIMP-free status\",\n      \"pmids\": [\"18077379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"MMP-9-positive neutrophil infiltration is associated with blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. The cleaved 85-kDa active form of MMP-9 is elevated in hemorrhagic areas, and laser capture microdissection confirmed high MMP-9 in microvessel endothelium and surrounding neutrophils at hemorrhagic sites.\",\n      \"method\": \"Gelatin zymography, immunohistochemistry, laser capture microdissection, human stroke tissue analysis\",\n      \"journal\": \"Stroke\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct tissue analysis with multiple methods but observational in human samples\",\n      \"pmids\": [\"18323498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Concomitant deficiency of MMP9 and uPA (but not tPA alone or uPAR alone) impairs normal gestation in mice. Combined lack of MMP9 and uPA exacerbates effects on bone growth and shows additive effects on cutaneous wound healing. MMP9 deficiency in wounds leads to compensatory upregulation of uPA activity, revealing a functional dependency between MMP9 and uPA in tissue repair.\",\n      \"method\": \"Double-gene knockout mice (MMP9/uPA, MMP9/tPA, MMP9/uPAR), gestation analysis, bone measurement, wound healing assay, uPA activity measurement\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis via multiple double-knockout combinations with defined phenotypes\",\n      \"pmids\": [\"21802414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MMP-9 is a multidomain enzyme with hemopexin (PEX), O-glycosylated, and catalytic domains supporting attachment, articulation, and catalysis, respectively. ProMMP-9 activation involves MMP-3 priming; meprins may destabilize the aminoterminus–fibronectin repeat interaction, and autocatalytic activation can occur when molecules bind the catalytic site displacing the cysteine from the zinc ion. The substrate repertoire extends from ECM to membrane-bound and intracellular proteins including crystallins, tubulins, and actins. The PEX domain exerts non-catalytic anti-apoptotic signaling. MMP-9 oligomers and heteromers (e.g., with NGAL) have distinct biological properties.\",\n      \"method\": \"Review synthesizing structural biology, degradomics, knockout mouse phenotype analysis, biochemical activation studies\",\n      \"journal\": \"Critical reviews in biochemistry and molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — comprehensive synthesis with direct experimental evidence across multiple labs; foundational mechanistic review\",\n      \"pmids\": [\"23547785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ADAM17 mediates LPS-induced MMP9 expression in lung epithelial cells (A549) via TNF-α/NF-κB signaling. Lentiviral RNAi knockdown of ADAM17 inhibits TNF-α shedding into supernatants, reduces IκBα phosphorylation and p65 phosphorylation, and decreases MMP9 expression in response to LPS, placing ADAM17 upstream of MMP9 in this pathway.\",\n      \"method\": \"Lentiviral RNAi, pharmacological NF-κB inhibitor (PDTC), TNFR1 blocking peptide, Western blot, ELISA\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RNAi epistasis with pharmacological confirmation in cell culture\",\n      \"pmids\": [\"23341882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TRPV4 activation provides a Ca2+ source necessary for rapid release and activation of MMP2 and MMP9 in intact mouse lung, contributing to septal barrier disruption and lung injury. TRPV4-/- lungs do not show MMP activation upon agonist treatment, and pharmacological MMP2/9 blockade (SB-3CT) protects against TRPV4-induced injury. TIMP-2 levels are decreased in TRPV4-injured lungs, increasing availability of active MMPs.\",\n      \"method\": \"TRPV4 knockout mice, TRPV4 agonist perfusion, Western blot for active MMP isoforms, pharmacological MMP inhibition, lung injury assessment\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological approaches in intact organ model\",\n      \"pmids\": [\"25150065\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Glioma cells induce MMP9 expression in microglia/macrophages via Toll-like receptor 2/6 (TLR2/6) signaling and p38 MAPK. TLR2-deficient mice show attenuated microglial MMP9 upregulation in experimental gliomas. Minocycline and p38 MAPK antagonists attenuate MMP9 and TLR2 upregulation in vitro. Glioma supernatant also upregulates TLR2 expression in microglia.\",\n      \"method\": \"TLR2-knockout mice, experimental glioma model, in vitro macrophage stimulation, minocycline and p38 inhibitor treatment\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout in vivo with pharmacological confirmation in vitro\",\n      \"pmids\": [\"24752463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ADAM15 upregulates MMP9 expression in lung cancer cells via MEK-ERK pathway activation and also proteolytically cleaves and activates pro-MMP9 directly in vitro, while interacting with MMP9 in vivo. Knockdown of MMP9 attenuates the invasive promotion by ADAM15 overexpression, placing ADAM15 as both an upstream regulator and direct activator of MMP9.\",\n      \"method\": \"shRNA knockdown, co-immunoprecipitation, in vitro pro-MMP9 cleavage assay, MEK-ERK inhibitor treatment, invasion assays\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro cleavage assay and co-IP with functional epistasis by knockdown\",\n      \"pmids\": [\"26323669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Endothelin-1 controls ventricular superoxide levels, which regulate MMP9 expression. In endothelin-1 hypomorphic mice, increased ventricular superoxide drives MMP9 overexpression, leading to reduced ventricular stiffness and dilated cardiomyopathy. A superoxide dismutase mimetic normalizes superoxide levels and reduces MMP9 overexpression, substantially improving cardiac function. Genetic ablation of MMP9 also improves cardiac function (without reducing superoxide), placing MMP9 downstream of superoxide in cardiac remodeling.\",\n      \"method\": \"Hypomorphic/hypermorphic allele mouse model, Cre-loxP switching, SOD mimetic treatment, MMP9 knockout, cardiac functional measurements\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological epistasis with multiple alleles and rescue experiments\",\n      \"pmids\": [\"25848038\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ATP6V1H deficiency in zebrafish dramatically increases mmp9 (and mmp13) expression, leading to reduced calcified bone cells and bone defects. Treatment of mutant embryos with MMP9/MMP13 small molecule inhibitors significantly restores bone mass, placing MMP9 downstream of V-ATPase activity in a pathway controlling bone formation.\",\n      \"method\": \"CRISPR/Cas9 knockout in zebrafish, pharmacological MMP inhibition rescue, skeletal staining, gene expression analysis\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with pharmacological rescue in vertebrate model\",\n      \"pmids\": [\"28158191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MMP9 promotes mesenchymal transition of pancreatic ductal adenocarcinoma cells via cleavage and activation of PAR1 (protease-activated receptor 1). Macrophage-secreted MMP9 was identified as the relevant PAR1 agonist by protease profiling and PAR1 cleavage assays. Inhibition of MMP9 and/or PAR1 limits macrophage-driven mesenchymal transition and reduces tumor cell survival against macrophage anti-tumor activity.\",\n      \"method\": \"PAR1 cleavage assays, MMP9/PAR1 inhibitors, medium transfer experiments, siRNA knockdown of ZEB1, tissue microarray correlation\",\n      \"journal\": \"Cellular oncology (Dordrecht, Netherlands)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — protease cleavage assay identifying specific substrate combined with inhibitor and knockdown experiments\",\n      \"pmids\": [\"32809114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Constitutive expression of MMP9 in the colonic epithelium (TgM9 mice) reduces reactive oxygen species, decreases DNA damage, and increases mismatch repair gene expression during colitis-associated cancer, suppressing tumor development via an 'MMP9-Notch1-ARF-p53 axis'. MMP9 siRNA-loaded nanoparticles that silence MMP9 in the colon increase ROS and DNA damage, confirming MMP9's tumor suppressor role in this context.\",\n      \"method\": \"Transgenic mouse model, siRNA nanoparticle knockdown, ROS measurement, DNA damage assays, mismatch repair gene expression\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic gain-of-function and siRNA loss-of-function with defined molecular readouts\",\n      \"pmids\": [\"32943603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Glucocorticoid-mediated stress enhances secretory autophagy via the stress-responsive co-chaperone FKBP51 (FK506-binding protein 51), leading to MMP9 secretion. Stress-enhanced MMP9 secretion increases cleavage of proBDNF to its mature form (mBDNF), as demonstrated by cellular assays and in vivo microdialysis, linking the stress response to synaptic plasticity via MMP9-mediated proBDNF processing.\",\n      \"method\": \"Cellular secretory autophagy assays, in vivo microdialysis, FKBP51 manipulation, proBDNF/mBDNF cleavage assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro evidence linking stress-induced MMP9 secretion to specific substrate cleavage\",\n      \"pmids\": [\"34330919\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PPARγ downregulates MMP9 expression after intracerebral hemorrhage by inhibiting NF-κB. Activation of PPARγ with rosiglitazone decreases NF-κB and MMP9; NF-κB inhibition (JSH-23) also suppresses MMP9 with limited effect on PPARγ. Protein co-IP confirmed direct interactions of NF-κB with PPARγ and MMP9 gene, and ChIP confirmed NF-κB binding to MMP9 promoter.\",\n      \"method\": \"In vivo and in vitro PPARγ agonist/antagonist treatment, NF-κB inhibitor, co-IP, ChIP, Western blot\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and co-IP combined with pharmacological epistasis in vivo and in vitro\",\n      \"pmids\": [\"33636289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Macrophage migration through ECM requires both MMP9-mediated degradation (mesenchymal migration mode) and Rac GTPase signaling. Inhibition of MMPs or Rac abolishes ECM degradation by macrophages and suppresses their ability to mobilize hematopoietic stem/progenitor cells in zebrafish embryos, demonstrating that MMP9-dependent mesenchymal migration is functionally linked to HSPC mobilization.\",\n      \"method\": \"Live imaging in zebrafish embryos, MMP inhibitors, Rac inhibitors, morphometric analysis, HSPC mobilization assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — real-time imaging with pharmacological inhibition and functional readout in vivo\",\n      \"pmids\": [\"33980872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HOCl (generated by an enzymatic MPO/H2O2/Cl- system) activates proMMP9 via oxidation of the cysteine switch mechanism, as demonstrated by fluorescence activity assays and gel zymography. Low nanomolar-to-low micromolar concentrations of chloramines formed from amino acids, serum albumin, and ECM proteins (laminin, fibronectin) also activate proMMP9, and this activation is diminished by the competitive HOCl-reactive species methionine. High HOCl concentrations inactivate active MMP9, establishing a concentration-dependent bidirectional redox regulation.\",\n      \"method\": \"Fluorescence activity assays, gel zymography, MPO enzymatic system, chloramine preparation, competitive inhibition with methionine\",\n      \"journal\": \"Antioxidants (Basel, Switzerland)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro biochemical reconstitution with multiple oxidant species and competitive inhibition controls\",\n      \"pmids\": [\"36009335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"LCN2, LOXL2, and MMP9 form a ternary protein complex: LCN2-LOXL2 and LCN2-MMP9 interactions occur both intracellularly and extracellularly, while LOXL2-MMP9 interactions only occur intracellularly. The LCN2/LOXL2/MMP9 complex enhances ECM proteolytic activity (fibronectin and Matrigel degradation), filopodia formation, microfilament rearrangement via profilin-1 upregulation, SPOCK1 expression, and FAK/AKT/GSK3β pathway activation.\",\n      \"method\": \"Protein-protein interaction assays (co-IP, PLA), co-overexpression functional studies, matrix degradation assays, in vivo tumor models, pathway analysis\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — protein interaction assays with functional downstream pathway characterization\",\n      \"pmids\": [\"37753805\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Active MMP9 drives ferroptosis by directly interacting with GPX4 (glutathione peroxidase 4) and glutathione reductase, reducing GPX4 expression and activity. MMP9 suppresses key transcription factors (SP1, CREB1, NRF2, FOXO3, ATF4) and GPX1 and FSP1, disrupting cellular redox balance. MMP9 also regulates iron metabolism by modulating iron import, storage, and export through a network of protein interactions. LC-MS/MS identified 83 proteins interacting with MMP9 at subcellular levels implicated in ferroptosis regulation.\",\n      \"method\": \"Engineered MMP9 construct without collagenase activity, LC-MS/MS protein interaction mapping, GPX4 activity assays, transcription factor expression analysis, integrated pathway analysis\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — novel MMP9 construct combined with MS-based interactome and functional enzyme assays; single lab\",\n      \"pmids\": [\"39252956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Dysadherin directly targets MMP9, and the dysadherin/MMP9 axis enhances ECM proteolytic activity, promotes CRC cell invasiveness, activates cancer-associated fibroblasts, and orchestrates ECM remodeling. In a humanized mouse model, dysadherin knockout reduces immunosuppressive and proangiogenic microenvironment, and these effects are reversed by MMP9 overexpression.\",\n      \"method\": \"Co-IP/direct targeting assays, MMP9 overexpression rescue, dysadherin knockout mouse model, ECM proteolytic activity assays, humanized mouse model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding assay with genetic rescue in mouse model\",\n      \"pmids\": [\"39613801\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The 92-kDa type IV collagenase gene (CLG4B/MMP9) was remapped from human chromosome 16 to chromosome 20 using somatic cell hybrid panel screening, FISH, and linkage analysis with a newly identified polymorphism.\",\n      \"method\": \"Somatic cell hybrid panel, FISH, linkage analysis\",\n      \"journal\": \"Cytogenetics and cell genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — three independent mapping methods converge on chromosomal localization\",\n      \"pmids\": [\"8978762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MMP-9 mediates Syndecan-4 (Sdc4) shedding under osteoarthritis conditions. MMP-9 (but not MMP-2) is elevated in cartilage, synovial membrane, and synovial fluid of OA patients and correlates with shed Sdc4 levels. siRNA knockdown and pharmacological inhibition of MMP-9 decrease shed Sdc4 in vitro. Increased Sdc4 shedding results in reduced ERK phosphorylation upon IL-1β stimulation, desensitizing chondrocytes to IL-1 signaling.\",\n      \"method\": \"siRNA knockdown, MMP inhibitors, ELISA, IHC, RT-qPCR, Western blot (pERK/ERK)\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA and inhibitor evidence for MMP-9 as sheddase with defined downstream signaling consequence\",\n      \"pmids\": [\"33246160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MMP-9 interacts with CD44 via its hemopexin (PEX) domain on the cell surface, while the catalytic domain cleaves CD44. A bispecific inhibitor (C9-PEX) simultaneously targeting both MMP9 catalytic and PEX domains and CD44 reduces MMP9 cellular levels, interferes with MMP9 homodimerization, and inhibits activation of the downstream MAPK/ERK pathway, demonstrating functional roles of both MMP9 domains in cancer cell invasiveness.\",\n      \"method\": \"Yeast surface display engineering, bispecific inhibitor design, cell-based functional assays for invasion, MMP9 dimerization assays, MAPK/ERK pathway analysis\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — domain-specific engineered inhibitors with multiple functional readouts\",\n      \"pmids\": [\"33600567\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MMP9 (gelatinase B) is a multidomain zinc-dependent endopeptidase secreted as a proenzyme that is activated extracellularly by MMP-3 (stromelysin) cleavage, by oxidants including HOCl/myeloperoxidase, and by ADAM15; its activity is regulated by TIMP-1/NGAL complex formation, RECK, thrombospondin-1, and cell-surface docking via CD44 or membrane vesicle shedding; it degrades ECM components (types I, III, IV, V collagen, gelatin, fibronectin, laminin) and non-ECM substrates including pro-TGF-β, IL-8 (potentiating chemotaxis), proBDNF, and Syndecan-4, and it controls critical biological processes including growth plate vascularization, hematopoietic stem cell mobilization (via Kit-ligand shedding), tumor angiogenesis (particularly as TIMP-free enzyme from neutrophils), bone marrow niche regulation, blood-brain barrier integrity, ferroptosis (via GPX4 and iron metabolism modulation), and synaptic plasticity; its transcription is driven by AP-1/NF-κB/Sp-1 promoter elements in response to TNFα, TPA, and tPA-LRP signaling, and is regulated epigenetically by DNA methylation and by upstream pathways including PPARγ-NF-κB, EGFR-PI3K-Akt, ERK/MAPK, and TLR2/p38 signaling.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"MMP9 (gelatinase B/92-kDa type IV collagenase) is a secreted zinc-dependent endopeptidase that functions as a central effector of extracellular matrix remodeling, inflammatory signaling, and tissue homeostasis across diverse biological contexts including wound healing, bone resorption, cerebrovascular integrity, synaptic plasticity, and tumor invasion. Secreted as an inactive zymogen, proMMP9 is activated extracellularly by proteolytic cleavage of its prodomain cysteine-switch — by proteases such as ADAM15 [PMID:26323669] and by myeloperoxidase-generated HOCl oxidation of the prodomain cysteine [PMID:36009335] — and its activity is opposed by TIMPs and modulated by TRPV4-dependent calcium influx [PMID:25150065]. Active MMP9 degrades ECM substrates (type IV collagen, fibronectin, laminin), cleaves cell-surface molecules including CD44 (via both its catalytic and hemopexin domains) [PMID:33600567], Syndecan-4 [PMID:33246160], and PAR1 (triggering mesenchymal transition) [PMID:32809114], and processes proBDNF to mature BDNF [PMID:34330919]. MMP9 transcription is driven by NF-κB binding at its promoter [PMID:33636289], NFATc1 downstream of RANKL/ROS/p38 signaling in osteoclasts [PMID:34801352], Smad3/Cited2/p300 upon TGF-β stimulation [PMID:16619037], and site-specific promoter CpG demethylation [PMID:23417766], with upstream regulators including endothelin-1/superoxide [PMID:25848038], MAPK7/ERK5 [PMID:32655131], and TLR2/6 [PMID:24752463].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Establishing the correct genomic location of MMP9 resolved prior mapping confusion and enabled proper linkage studies: the gene was remapped from chromosome 16 to chromosome 20.\",\n      \"evidence\": \"Somatic cell hybrid panel, FISH, and linkage analysis with novel polymorphism\",\n      \"pmids\": [\"8978762\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No functional consequence of the remapping was explored\", \"Regulatory elements at the locus not characterized\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"The question of how TGF-β activates MMP9 transcription was answered by identifying the Smad3/Cited2/p300 coactivator complex at the MMP9 promoter, establishing a direct transcriptional mechanism for cytokine-driven MMP9 induction in cancer invasion.\",\n      \"evidence\": \"Co-IP, GST-pulldown, mammalian two-hybrid, ChIP at MMP9 promoter, siRNA knockdown in MDA-MB-231 cells with Matrigel invasion readout\",\n      \"pmids\": [\"16619037\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Cited2/Smad3 occupancy is constitutive or stimulus-dependent at endogenous locus not fully resolved\", \"Contribution of other Smad cofactors not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Genetic epistasis between MMP9 and urokinase plasminogen activator (uPA) revealed that these two proteolytic systems cooperate non-redundantly in wound healing, bone growth, and gestation, establishing that MMP9 cannot be fully compensated by the plasminogen system.\",\n      \"evidence\": \"Double-knockout mouse models (Mmp9−/− × uPA−/−, Mmp9−/− × tPA−/−) with wound healing, bone growth, and gestation phenotyping\",\n      \"pmids\": [\"21802414\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific shared substrates mediating the epistatic interaction not identified\", \"Whether compensatory mechanisms differ across tissue types is unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Two parallel discoveries established how MMP9 transcription is regulated by NF-κB: one placed ADAM17→TNF-α→TNFR1→NF-κB upstream of MMP9 in epithelial cells, while another showed that TNFα induces site-specific CpG demethylation at −36 bp in the MMP9 promoter, providing an epigenetic memory mechanism for persistent upregulation.\",\n      \"evidence\": \"Lentiviral RNAi of ADAM17 with NF-κB inhibitor and TNFR1 blocking peptide (epithelial cells); bisulfite sequencing PCR and dual-luciferase reporter for CpG methylation (keratinocytes)\",\n      \"pmids\": [\"23341882\", \"23417766\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether demethylation at −36 bp is NF-κB-dependent or a parallel event not resolved\", \"Demethylating enzyme identity unknown\", \"Single cell types per study\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Three studies converged to place MMP9 downstream of distinct upstream activating signals — TRPV4-Ca²⁺ in lung injury, TLR2/6-p38 in microglia, and hyperhomocysteinemia in cerebrovascular permeability — each using genetic knockouts for epistasis, demonstrating that MMP9 serves as a common effector across tissue-specific inflammatory cascades.\",\n      \"evidence\": \"TRPV4−/− mouse lungs with pharmacological MMP inhibition; TLR2-deficient mice with glioma model; Cbs+/−/Mmp9−/− double-KO mice with cerebrovascular permeability assays\",\n      \"pmids\": [\"25150065\", \"24752463\", \"24865997\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TRPV4-mediated MMP9 activation is transcriptional or post-translational not fully distinguished\", \"Direct MMP9 substrates in cerebrovascular permeability beyond VE-cadherin not catalogued\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"The mechanism of proMMP9 activation was expanded beyond classical protease cascades when ADAM15 was shown to directly cleave and activate proMMP9, and endothelin-1/superoxide was placed upstream of MMP9 expression in cardiac remodeling via genetic epistasis.\",\n      \"evidence\": \"In vitro proMMP9 cleavage by ADAM15 with co-IP and Matrigel invasion (lung cancer); Edn1 hypomorph × Mmp9−/− double mutant mice with SOD mimetic (cardiac function)\",\n      \"pmids\": [\"26323669\", \"25848038\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ADAM15 cleavage site on proMMP9 not mapped\", \"Whether ADAM15-MMP9 axis operates in non-cancer tissues is unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Multiple studies identified new cell-surface substrates of MMP9 — PAR1 cleavage drives macrophage-induced mesenchymal transition in PDAC, Syndecan-4 shedding desensitizes chondrocytes to IL-1β, and NFATc1 was established as the transcription factor mediating RANKL-driven MMP9 expression in osteoclasts — collectively broadening MMP9's substrate repertoire and transcriptional control beyond ECM degradation.\",\n      \"evidence\": \"PAR1 cleavage assay with MMP9/PAR1 inhibitors and siRNA in PDAC; Sdc4 shedding assay with siRNA and MMP inhibitor in chondrocytes; NFATc1 nuclear translocation with RANKL/ROS/p38 pathway inhibition in osteoclasts\",\n      \"pmids\": [\"32809114\", \"33246160\", \"34801352\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PAR1 cleavage site by MMP9 not precisely mapped\", \"Whether Sdc4 shedding by MMP9 occurs in vivo not directly demonstrated\", \"Relative contribution of NFATc1 vs. NF-κB to MMP9 transcription in osteoclasts not quantified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"MMP9's extracellular substrate range was further extended to proBDNF processing (via secretory autophagy), and the MMP9 hemopexin domain was shown to be functionally separable from its catalytic domain — mediating CD44 interaction and homodimerization — establishing a dual-domain model for MMP9 function.\",\n      \"evidence\": \"Secretory autophagy pathway manipulation with in vivo microdialysis (proBDNF→mBDNF); engineered N-TIMP2 variant targeting catalytic domain and PEX-domain separately with invasion and ERK signaling readouts\",\n      \"pmids\": [\"34330919\", \"33600567\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether proBDNF cleavage by MMP9 is direct or requires co-factors in vivo not fully resolved\", \"Structural basis of PEX domain–CD44 interaction not determined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"The long-hypothesized oxidative activation of proMMP9 was mechanistically demonstrated: myeloperoxidase-derived HOCl directly oxidizes the prodomain cysteine-switch, and chloramines formed from HOCl reactions with amino acids and ECM proteins also activate proMMP9, while excess HOCl inactivates the enzyme — providing a redox rheostat for MMP9 activity at inflammatory sites.\",\n      \"evidence\": \"Fluorescence activity assays and gel zymography with enzymatic MPO/H₂O₂/Cl⁻ system and competitive methionine inhibition\",\n      \"pmids\": [\"36009335\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of chloramine-mediated activation not tested\", \"Whether HOCl-activated MMP9 has altered substrate specificity is unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"The discovery that LCN2, LOXL2, and MMP9 form a ternary complex — with compartment-specific interactions — established that MMP9 operates within multi-enzyme complexes that enhance ECM degradation and activate FAK/AKT signaling, and active MMP9 was spatially mapped to myeloid cells at tissue remodeling sites using an isoform-specific antibody.\",\n      \"evidence\": \"Reciprocal Co-IP for ternary complex with fibronectin/Matrigel degradation and signaling assays; novel anti-active-MMP9 antibody (F107) with IHC on IBD fistulae and hidradenitis suppurativa tissues\",\n      \"pmids\": [\"37753805\", \"36810514\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stoichiometry and structural basis of LCN2-LOXL2-MMP9 complex unknown\", \"Whether ternary complex exists in non-tumor contexts not tested\", \"F107 antibody not yet independently validated by other groups\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"MMP9 was linked to two new functional axes: dysadherin directly binds MMP9 and the dysadherin/MMP9 axis drives colorectal cancer invasion and fibroblast activation; separately, MMP9 was found to interact with GPX4 and modulate ferroptosis by suppressing GPX4 activity and altering iron metabolism, extending MMP9 function beyond proteolysis.\",\n      \"evidence\": \"Co-IP of dysadherin-MMP9 with KO rescue in humanized mouse model; MMP9 domain mutant + LC-MS/MS interactome identifying GPX4 interaction with ferroptosis functional readouts\",\n      \"pmids\": [\"39613801\", \"39252956\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Dysadherin–MMP9 binding interface not mapped\", \"GPX4 interaction with MMP9 not independently replicated\", \"Whether MMP9-ferroptosis link requires catalytic activity or is scaffolding-based is unclear\", \"LC-MS/MS interactome from single study needs orthogonal validation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of MMP9's hemopexin-domain interactions with CD44 and binding partners, the in vivo significance of oxidative (HOCl/chloramine) versus proteolytic activation pathways, the full extent of non-proteolytic MMP9 functions (e.g., ferroptosis regulation via GPX4), and how tissue-specific transcriptional programs (NF-κB, NFATc1, Smad3/Cited2) are integrated to determine MMP9 output in different cell types.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal structure of full-length MMP9 with hemopexin domain–partner complexes\", \"Relative contribution of oxidative vs. proteolytic activation in vivo unknown\", \"Non-proteolytic functions (ferroptosis, scaffolding) not independently replicated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 3, 4, 8, 18, 2]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 4, 14, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 2, 3, 4, 14, 23]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [12, 13, 14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [0, 4, 9, 12, 13, 14]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [11, 16, 17, 23]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 18, 19]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 10, 13, 19, 25]}\n    ],\n    \"complexes\": [\n      \"LCN2-LOXL2-MMP9 ternary complex\"\n    ],\n    \"partners\": [\n      \"CD44\",\n      \"LCN2\",\n      \"LOXL2\",\n      \"ADAM15\",\n      \"GPX4\",\n      \"FKBP5\",\n      \"CITED2\",\n      \"FXYD5\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"MMP9 (gelatinase B) is a secreted zinc-dependent endopeptidase that functions as a central regulator of extracellular matrix remodeling, angiogenesis, and immune cell mobilization. Secreted as a 92-kDa glycosylated proenzyme, it is activated by MMP-3-mediated stepwise propeptide cleavage, by HOCl/myeloperoxidase-generated oxidants acting on the cysteine switch, and by ADAM15, while its activity is constrained by TIMP-1 complexation, RECK, and thrombospondin-1 [PMID:1371271, PMID:36009335, PMID:9789069, PMID:11606713]. MMP9 degrades collagens (types I, III, IV, V), gelatin, and non-ECM substrates including latent TGF-β (via CD44-mediated cell-surface docking), IL-8 (potentiating neutrophil chemotaxis ~10-fold), Kit-ligand (enabling hematopoietic stem cell mobilization from bone marrow niches), Syndecan-4, PAR1, and proBDNF, thereby linking proteolysis to angiogenesis, stem cell trafficking, inflammation, and synaptic plasticity [PMID:10652271, PMID:11023497, PMID:12062105, PMID:33246160, PMID:34330919]. Transcription is driven by cooperative AP-1, NF-κB, and Sp-1 promoter elements in response to TNF-α, TPA, tPA-LRP signaling, and TLR2/p38 signaling, with PPARγ serving as a negative regulator through NF-κB inhibition [PMID:8426746, PMID:12960961, PMID:33636289].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Identification of MMP9 as a distinct 92-kDa secreted metalloproteinase with a five-domain architecture and type IV/V collagenase activity established it as a new MMP family member with unique structural features including a collagen V-homologous proline-rich domain.\",\n      \"evidence\": \"Protein purification, NH2-terminal sequencing, substrate digestion assays from SV40-transformed fibroblasts, macrophages, and fibrosarcoma cells\",\n      \"pmids\": [\"2551898\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure of full-length proMMP-9 not yet resolved\", \"Physiological activators in vivo unknown\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Demonstration that MMP-3 activates proMMP-9 through sequential propeptide cleavage at specific bonds (Glu40-Met41, Arg87-Phe88) established the paradigm of inter-MMP zymogen activation cascades, while TIMP-1 was shown to block intermediate-to-active conversion.\",\n      \"evidence\": \"In vitro reconstitution with purified enzymes, NH2-terminal sequencing of cleavage products, substrate digestion with multiple protease panels\",\n      \"pmids\": [\"1371271\", \"1400481\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of different activators in specific tissue contexts unknown\", \"Structural basis of TIMP-1 inhibition of the intermediate not resolved\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Mapping the transcriptional control of MMP9 to synergistic AP-1, NF-κB, and Sp-1 promoter elements explained how inflammatory cytokines (TNF-α) and phorbol esters (TPA) drive MMP9 induction, establishing the transcriptional framework for MMP9 regulation.\",\n      \"evidence\": \"Promoter deletion/mutation luciferase reporters, EMSA nuclear factor binding assays in osteosarcoma cells\",\n      \"pmids\": [\"8426746\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chromatin-level regulation (histone modifications, DNA methylation) not yet examined\", \"Cell-type-specific enhancer usage not defined\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"MMP9-null mice revealed that MMP9 is required for growth plate vascularization, hypertrophic chondrocyte apoptosis, and ossification, and bone marrow transplantation rescue proved that bone-marrow-derived cells are the critical MMP9 source, establishing MMP9 as an angiogenic switch in skeletal development.\",\n      \"evidence\": \"Gene knockout mice, bone marrow transplantation rescue, organ culture angiogenesis assays\",\n      \"pmids\": [\"9590175\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct angiogenic substrate released by MMP9 in growth plate not molecularly identified\", \"Redundancy with other MMPs in ossification not fully tested\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Three discoveries converged to define MMP9's non-ECM substrate repertoire and cell-surface regulation: CD44 was identified as a docking receptor localizing active MMP9 to the cell surface for TGF-β activation; inflammatory cell-derived MMP9 was shown to drive multistage skin carcinogenesis; and MMP9 was found to process IL-8 into a 10–27-fold more potent neutrophil chemotactic form.\",\n      \"evidence\": \"Co-immunoprecipitation and TGF-β cleavage assays; bone marrow chimera experiments in HPV16 transgenic mice; in vitro IL-8 cleavage with Ca²⁺ flux and chemotaxis readouts\",\n      \"pmids\": [\"10652271\", \"11081634\", \"11023497\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full repertoire of non-ECM substrates not systematically catalogued\", \"Structural basis of CD44–MMP9 PEX domain interaction not resolved at atomic level\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Discovery that NGAL stabilizes MMP9 against degradation (preserving enzymatic activity) and that thrombospondin-1 suppresses proMMP-9 activation in vivo revealed two opposing extracellular regulators that tune MMP9 bioavailability beyond TIMP-based inhibition.\",\n      \"evidence\": \"In vitro reconstitution of NGAL–MMP9 complex; TSP1-knockout/overexpression mice with in vitro activation suppression assays\",\n      \"pmids\": [\"11486009\", \"11606713\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structural basis of NGAL–MMP9 complex not fully defined\", \"Whether TSP1 directly binds proMMP9 or acts indirectly not conclusively resolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"MMP9 was placed at the center of hematopoietic stem cell mobilization: SDF-1-induced MMP9 releases soluble Kit-ligand from the bone marrow niche, enabling c-Kit+ stem cell transfer to proliferative niches, as demonstrated by impaired sKitL release and HSC motility in MMP9−/− mice rescued by exogenous sKitL.\",\n      \"evidence\": \"MMP9 knockout mice, BM ablation, exogenous sKitL rescue, stem cell mobilization assays\",\n      \"pmids\": [\"12062105\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MMP9 cleaves Kit-ligand directly or via intermediate protease not fully resolved\", \"Contribution of other MMPs to sKitL shedding not excluded\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Parallel discoveries showed MMP9 contributes to aortic aneurysm formation (cooperatively with MMP-2 from distinct cell sources) and is released on membrane vesicles by endothelial cells during angiogenesis, while MMP9 induction in premetastatic lungs via VEGFR-1 signaling promotes metastatic colonization.\",\n      \"evidence\": \"Double-KO mice with macrophage reinfusion for AAA; vesicle ultrastructure/zymography/invasion assays; VEGFR-1 TK and MMP9 deletion metastasis models\",\n      \"pmids\": [\"12208863\", \"11839588\", \"12398893\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific ECM substrates degraded by vesicle-associated MMP9 not identified\", \"Whether vesicle-mediated MMP9 delivery is regulated independently of soluble secretion unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"tPA was shown to upregulate MMP9 expression in brain endothelium via LRP signaling, linking the fibrinolytic system to MMP9-mediated blood-brain barrier degradation during stroke.\",\n      \"evidence\": \"RNAi knockdown of LRP, tPA-knockout mice, focal cerebral ischemia model\",\n      \"pmids\": [\"12960961\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling cascade from LRP to MMP9 transcription not fully delineated\", \"Whether LRP-MMP9 axis is relevant in non-stroke neurological injury unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"The discovery that neutrophils uniquely release TIMP-free proMMP-9—which upon activation is an exceptionally potent proangiogenic stimulus at subnanomolar concentrations—explained why neutrophil-derived MMP9 has disproportionate biological impact compared to MMP9 from other sources.\",\n      \"evidence\": \"Granule purification, stoichiometric TIMP-1 complexation, in vivo chick CAM angiogenesis assay\",\n      \"pmids\": [\"18077379\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which neutrophils package MMP9 without TIMP not determined\", \"Whether TIMP-free status is regulated under different inflammatory conditions unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Endothelin-1/superoxide/MMP9 epistasis experiments established MMP9 as an effector of oxidative-stress-driven cardiac remodeling: superoxide upregulates MMP9, and genetic ablation of MMP9 rescues dilated cardiomyopathy independently of superoxide levels.\",\n      \"evidence\": \"Endothelin-1 hypomorphic mice, SOD mimetic rescue, MMP9 knockout, cardiac functional measurements\",\n      \"pmids\": [\"25848038\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific cardiac ECM substrates degraded by MMP9 in this context not identified\", \"Whether MMP9 catalytic activity or non-catalytic PEX signaling mediates the phenotype unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"MMP9's substrate repertoire was extended to include PAR1 on pancreatic cancer cells (promoting mesenchymal transition) and Syndecan-4 in osteoarthritic cartilage (desensitizing chondrocytes to IL-1β signaling), demonstrating context-specific signaling consequences of MMP9-mediated ectodomain shedding.\",\n      \"evidence\": \"PAR1 cleavage assays with MMP9/PAR1 inhibitors; Sdc4 siRNA/inhibitor knockdown with pERK readout in chondrocytes\",\n      \"pmids\": [\"32809114\", \"33246160\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural determinants of MMP9 selectivity for PAR1 vs other PARs not defined\", \"In vivo validation of Sdc4 shedding by MMP9 in animal OA models lacking\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"MMP9 was linked to stress-induced synaptic plasticity: glucocorticoid-driven secretory autophagy via FKBP51 releases MMP9, which cleaves proBDNF to mature BDNF in vivo, connecting neuroendocrine stress signaling to MMP9-dependent neurotrophin processing.\",\n      \"evidence\": \"Cellular secretory autophagy assays, in vivo brain microdialysis, FKBP51 manipulation, proBDNF/mBDNF cleavage measurement\",\n      \"pmids\": [\"34330919\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether MMP9 cleaves proBDNF directly or via plasmin cascade not fully distinguished\", \"Relevance to chronic stress and psychiatric phenotypes not established in knockout models\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Biochemical reconstitution of the HOCl/myeloperoxidase-mediated cysteine switch oxidation mechanism showed concentration-dependent bidirectional regulation: low-concentration oxidants activate proMMP9, while high concentrations inactivate the enzyme, providing a rheostat for inflammatory MMP9 control.\",\n      \"evidence\": \"Fluorescence activity assays, gel zymography, MPO enzymatic system, competitive methionine inhibition\",\n      \"pmids\": [\"36009335\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo concentrations of HOCl at inflammatory sites relative to activation/inactivation thresholds not measured\", \"Whether other MMPs share the same bidirectional redox sensitivity unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Two studies expanded MMP9 biology into ferroptosis and tumor microenvironment remodeling: MMP9 was found to interact with GPX4 and modulate iron metabolism to drive ferroptosis, and the dysadherin–MMP9 axis was shown to activate cancer-associated fibroblasts and remodel the immunosuppressive microenvironment.\",\n      \"evidence\": \"LC-MS/MS interactome mapping with engineered MMP9 construct and GPX4 activity assays; co-IP/knockout rescue in humanized mouse model for dysadherin–MMP9\",\n      \"pmids\": [\"39252956\", \"39613801\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"MMP9–GPX4 interaction mechanism (catalytic cleavage vs binding-mediated inhibition) not distinguished\", \"Ferroptosis findings from single lab with engineered construct require independent replication\", \"Dysadherin–MMP9 binding interface not structurally characterized\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of full-length MMP9 activation and substrate selection, the relative in vivo contributions of catalytic versus non-catalytic (PEX domain) functions, and whether MMP9-driven ferroptosis and intracellular roles represent physiologically relevant activities or artifacts of overexpression systems.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of full-length proMMP9 in complex with activators or substrates\", \"Catalytic vs PEX-mediated non-catalytic signaling contributions not genetically separated in vivo\", \"Intracellular MMP9 substrates (tubulins, crystallins) lack in vivo validation\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 2, 8, 28, 38]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 2, 6, 33]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [0, 4, 6, 34, 36]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 9, 13, 18]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6, 39]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [0, 2, 4, 12, 34, 36]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 8, 14, 18, 24]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 6, 15, 22, 31]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 27]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [11, 32]}\n    ],\n    \"complexes\": [\n      \"proMMP-9/TIMP-1 complex\",\n      \"MMP-9/NGAL (LCN2) complex\",\n      \"LCN2/LOXL2/MMP9 ternary complex\"\n    ],\n    \"partners\": [\n      \"TIMP1\",\n      \"LCN2\",\n      \"CD44\",\n      \"MMP3\",\n      \"RECK\",\n      \"THBS1\",\n      \"ADAM15\",\n      \"LOXL2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}